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Background: Current management of patients presenting with acute coronary 
syndrome (ACS) includes aggressive and expeditious revascularisation, including 
surgical revascularisation. However, early surgery following ACS is associated with 
high mortality, as subsequent global ischaemia induced during surgery is imposed on 
infarcted myocardium. Emerging evidence suggests that matrix metalloproteinases 
(MMPs), especially MMP2, may have an important role in the acute myocardial 
dysfunction seen after global ischaemia-reperfusion injury, by targeting intracellular 
functional and structural proteins.  
Aims: To investigate whether MMP2 has a causative role in heart dysfunction when 
previously infarcted hearts were subjected to further global ischaemia-reperfusion, as 
occurs in cardiac surgery, with and without cardioplegic protection. 
Methods and Results: MI was surgically induced in male Wistar rats, (250-350 g body 
weight) by in vivo ligation of the left anterior descending artery. The animals were 
recovered for 7 days prior to excision of hearts and isolated Langendorff perfusion, 
followed by induction of further global ischaemia and reperfusion. The recovery of 
mechanical function (left ventricular developed pressure: LVDP) of the heart was 
assessed during reperfusion. MMP2 activity was also measured during the early 
reperfusion phase in the heart tissues. Infarcted hearts had less capacity to recover 
function after an additional period of global ischaemia, which was associated with 
higher MMP2 activity in the infarcted hearts compared to normal hearts. Inhibition of 
MMP2 improved recovery of function. When an MMP inhibitor was used as an adjunct 
to St Thomas’ Hospital cardioplegia, there was a trend towards improved recovery if the 
inhibitor was present before, during and after ischaemia. 
Conclusion: MMP2 has a role in causing cardiac dysfunction when infarcted hearts 
were subjected to further global ischaemia-reperfusion. Inhibition of MMP2 resulted in 
improved recovery of the function of the hearts during reperfusion. With cardioplegia, 
MMP2 inhibition before, during and after ischaemia was crucial to improve 
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1 INTRODUCTION 
1.1 Ischaemic heart disease (IHD) 
In the UK, ischaemic heart disease (IHD) is very common. More than 1.4 million 
people suffer from angina, with 275,000 having a heart attack every year 1, 2. It remains 
the number one killer in Western society. In 2010, one in five men and one in ten 
women died from deaths due to heart disease 3. There were about 495,000 episodes of 
inpatient hospital admission due to ischaemic heart disease in 2011 3. Hence, it 
continues to impose a significant health and economic burden in this country.   
 
1.2 Pathophysiology of ischaemic heart disease 
IHD or myocardial ischaemia, occurs when perfusion or blood flow to the myocardium 
is inadequate to meet its metabolic demand. This is due to narrowing or obstruction of 
the coronary arteries from atheriosclerosis, thrombosis, embolism or spasm. It is more 
common in men, and the risk of IHD is increased in smokers, people with diabetes 
mellitus, hypertension, hypercholesterolaemia and family history of IHD. It can present 
as a chronic disease with chest pain or angina on exertion. However, it can also present 
acutely with sudden onset of chest pain, chest pain at rest or rapidly worsening chest 
pain. The acute presentation is now known as acute coronary syndrome (ACS), which 
includes the classical full-thickness or transmural myocardial infarction (MI). 
Atheriosclerosis is by far the commonest cause of coronary artery disease 4. Risk factors 
mentioned above result in damage to the endothelium, which in turn initiates a cascade 
of events leading to the formation of atheroma within the endothelium. Atheroma is 
classically composed of a fibrous cap with a lipid rich core. With endothelial damage, 
there is upregulation of adhesion molecules on the endothelial surface, causing 
transmigration of blood leucocytes such as mononuclear lymphocytes and T-cell 
phagocytes into the intima of the arterial wall 5. As a consequence, smooth muscle cells 
(SMC) migrate from the tunica media into the intima layer. Once in the intima, SMCs 
continue to proliferate and secrete matrix metalloproteinases (MMPs) in response to its 
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environment. MMPs, in turn, modulate vascular cells causing activation, proliferation, 
migration, cell death, geometric remodelling and destruction of the extracellular matrix 
(ECM) of the arteries or myocardium. These changes will further propagate the 
inflammatory process resulting in a vicious cycle, with further development of the 
atheromatous plaques and remodelling of the arteries.  
ACS arises due to acute disruption to the atheromatous plaques 5, 6. There could be a 
through and through rupture of the fibrous cap (which is often fatal), superficial erosion 
of the cap, intraplaque haemorrhage or erosion of a calcified nodule (Fig 1.1).  
 
Figure 1.1 Microanatomy of coronary arterial thrombosis and acute occlusion. 5 
 
Disruption of atheromatous plaque exposes the collagen in the plaque ECM and 
activates platelets, whereas tissue factor (TF) secreted by the SMCs and macrophages 
activates the coagulation cascade. Besides, circulating plasminogen activator inhibitor-1 
(PAI-1) in the blood comes in contact with the disrupted plaques, which also serves to 
increase the general thrombogenicity of the blood. As a result, thrombosis occurs and 
causes intraluminal obstruction of blood flow to the myocardium, resulting in the 
clinical symptoms experienced by patients. 
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The infarcted myocardium undergoes coagulative necrosis, with inflammatory changes 
such as neutrophil infiltration 7, followed by necrotic myocyte resorption, infiltration of 
fibroblasts and scar tissue formation and endothelial cell activation and 
neovascularisation. There are also complex structural and architectural changes as the 
myocardium heals and remodels 8, with thinning and dilation of the infarct zones and 
compensatory hypertrophy of the non-infarct zones. Depending on the severity, duration 
and location of the infarct, there are several possible complications as a consequence of 
myocardial infarction. These are cardiogenic shock, ventricular dysfunction, 
arrhythmias, myocardial ruptures (such as septal or free wall rupture), infarct extension 
and expansion. Myocardial infarction, with the consequent remodelling of the LV, 
could also ultimately lead to chronic heart failure in the long term.  
Over the years, as a result of ongoing laboratory research, with clinical correlation, our 
understanding of the anatomy and biology of coronary arteriosclerosis have evolved. 
Inflammation is now known to be a central pathological process in all stages of 
atherogenesis 5. Any important mediators of inflammation could be potential targets to 
reduce the risk of plaque rupture and limit the damage caused by the disease. 
Considering its likely role in plaque destabilisation and matrix remodelling, MMPs have 
emerged as proteins of interest in coronary artery disease.  
 
1.3 Matrix metalloproteinases  
Matrix metalloproteinases (MMPs) are a ubiquitous group of zinc-containing 
endopeptidases involved in degradation of ECM, and mediating a variety of 
physiological functions such as embryogenesis, growth, angiogenesis and wound 
healing 9-12. In addition, MMPs are involved in pathological processes, causing 
architectural extracellular matrix changes by participating in inflammation and 
carcinogenesis, vascular remodelling, advancing or destabilising atherosclerotic 
plaques, as well as inducing myocyte hypertrophy, apoptosis and interstitial fibrosis 11-
15. The parallel expansion in the understanding of the biology of the ECM (which is a 
dynamic structure rather than just a static structural scaffold) and the discovery of a vast 
and diverse array of non-ECM MMP substrates has gradually shifted the conventional 
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view of MMPs as destructive enzymes to important regulators in various cell-signalling 
processes 14. 
1.3.1 Classification of MMPs  
The classification of MMPs can be somewhat confusing. MMPs can be broadly divided 
into 4 different groups according to the substrate it acts on, or they can be classified 
numerically 12; thus collagenases include MMP1 and MMP8, gelatinases include MMP2 
and MMP9, stromelysins consist of MMP3, MMP10 and MMP11, and others such as 
MMP7, MMP12 and MT-MMP.  
The protein structure of the different groups of MMPs is shown in Fig 1.2. The pro-
domain, or NH2-terminal domain, consists of about 80 amino acids and is made up of 
the signalling sequence and pro-peptide. The signalling sequence allows for secretion of 
the enzyme into the endoplasmic reticulum and transport out of the cell, whereas the 
pro-peptide sequence contains the cysteine switch. The cysteine switch plays a key role 
in activation of MMPs; this will be described in more detail in subsequent sections. 
Next is the catalytic domain, which is made up of about 170 amino acids, and also 
contains the zinc-binding motif. The cysteine switch in the pro-peptide domain and the 
zinc in the catalytic domain co-ordinate to maintain the enzyme in an inactive state. 
This NH2-terminal domain and the zinc-binding motif form the common structural 
signature of MMPs. A flexible linker/hinge region joins the structure to the hemopexin 
domain. The hinge region is of different lengths in different MMPs, and is also absent in 
some MMPs such as MMP7, MMP23 and MMP26. The hemopexin domain, about 200 
amino acids long, confers substrate specificity to MMPs by co-ordination of protein-
protein interaction 11-13. The hemopexin domain is linked to a C-terminal tail. 
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Figure 1.2 The structure of MMP. 
MMPs consist of a pro-domain with cysteine switch, catalytic domain, joined by a 
linker/hinge region to the hemopexin domain. 13 
 
In tissues, MMPs are involved in degradation and removal of extracellular matrix. As 
the extracellular matrix is a dynamic structure, any alteration to its structure will alter 
cell-matrix and cell-cell interaction. There are abundant growth factors and bioactive 
molecules such as chemokines, cytokines and growth factors that are bound to the 
ECM. By altering the structure of the ECM, MMPs are therefore involved in the 
regulation, release and activation of these molecules. Hence, MMPs are important 
participants in the regulatory pathways in cellular proteolysis 11.  
1.3.2 Regulation of MMPs  
MMPs are tightly regulated at various levels due to their potential hazardous proteolytic 
activities. The earliest control of their activity is mediated via the modulation of their 
gene expression. The gene expression of MMPs can be stimulated by various factors. 
Up-regulation of MMP gene could be effected by soluble mediators such as growth 
factors and cytokines, cell-cell interaction, cell-matrix interaction and signaling 
pathways 16. Bioactive molecules such as angiotensin II (ANGII), endothelin (ET) and 
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cytokines, typically tumour necrosis factor (TNF) and interleukin 1β (IL-1β), activate 
various signaling pathways such as Janus kinase-signal transducers and activators of 
transcription (JAK-STAT) pathway, protein kinase-C and mitogen-activated protein 
kinase (MAPK) pathways, which in turn increases gene expression of various MMPs 12. 
Mechanical stimuli such as changes in the cyclical myocardial strain pattern due to 
myocardial ischaemia, and manifested by the deformation in LV dimensions during the 
cardiac cycle, have also been shown to increase MMP expression 17, 18. However, it is 
not entirely certain whether this is due to a direct action on transcription factors, or 
indirectly via oxidative stress and inflammatory markers in the myocardium that were 
also raised under these circumstances. Cell-cell and cell-matrix interaction, such as 
extracellular matrix metalloproteinase inducer protein (EMMPRIN), may also be an 
important factor in regulating the transcription of MMPs 19. On the other hand, growth 
factors, via activation of SMAD pathways, could decrease the expression of MMPs.  
MMPs are secreted as an inactive pro-enzyme into the extracellular environment and 
require stepwise activation (Fig 1.3). Initially, a conformational change leads to the 
disruption of the cysteine-zinc interaction, hence allowing a water molecule to bind to 
the catalytic zinc 10, 12, 13, 20. There are a variety of triggers for this to occur. 
Conventionally, direct cleavage of the pro-domain (resulting in lower molecular weight 
MMPs), activates MMPs. Direct proteolysis of the pro-domain may be a result of an 
interaction between S-reactive agents, organomercurial compounds or reactive oxygen 
species and the conserved cysteine in the pro-domain. Alternatively, binding of 
chaotropic agents or detergents could also lead to the conformational change required to 
trigger the autocatalysis resulting in the stepwise degradation of the pro-domain 21. 




Figure 1.3 Schematic diagram of step-wise activation of pro-MMPs.  
The top pathway represents the proteolytic pathway and the bottom pathway, the 
non-proteolytic pathway. The propeptide is represented by the black line with the 
black rectangle representing the bait region, where proteolysis occurs. C=cysteine 
switch, SH=sulfhydryl of cysteine, SX=cysteine switch. Chemical activation requires 
modification of SX, resulting in partial activation of MMP2, with intermolecular 
processing completing the activation process. 20. 
 
More recently, it was discovered that direct cleavage of the pro-enzyme is not a 
necessary step to activate the MMPs. Allosteric reconformation or chemical 
modification of the pro-domain by thiol-modifying agents could also activate the MMPs 
22.  Binding of macromolecules, or other proteins such as bone sialoproteins to pro-
MMP2, could bring about the necessary allosteric reconformation 23. Peroxynitrite and 
glutathione cause S-glutathiolation of cysteine, which will activate the MMPs 24-26. 
There is recent evidence to suggest that phosphorylation and S-nitrosylation may also 
be important in regulating the activity of MMP 13, 27, 28; however, the identities of the 
kinases and phosphatases that are involved are yet to be elucidated. These kinases and 
phosphatases may be novel targets involved in modulating the activity of MMP and its 
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impact on mechanical dysfunction of the myocardium. The other aspect of post-
translational modification is localization or compartmentalization of MMPs so that it 
comes into contact with its potential substrate 21, 29. This is facilitated by exosites, 
substrate-binding motifs outside the catalytic areas, and binding partners in the 
respective compartments. The exosites may also be important in the degradation of 
certain substrates and activation of intracellular signaling leading to events such as 
apoptosis. 
Activated MMPs interact with their endogenous inhibitors; in tissues, tissue inhibitors 
of MMPs (TIMPs) and in circulating plasma, α-macroglobulin 12, 13. They bind to 
MMPs in a 1:1 stoichiometric manner, and when bound will inactivate MMPs. The net 
activity of MMPs is a fine balance between activation and degradation. The tissue 
inhibitors of MMP (TIMP) and the complexes formed between MMPs and other 
proteins (proteoglycan core proteins and/or their glycosaminoglycan chains) are 
involved in the regulation of the balance between activation and degradation of MMPs.  
 
1.3.3 Myocardial MMPs and Coronary Heart Disease 
MMPs were first studied using zymography in patients undergoing heart transplantion. 
In the heart, MMPs are located within the endothelium, the subendothelial space of the 
endocardium and the interstitial space, usually in association with TIMPs 30. The full 
spectrum of MMPs and TIMPs are found in the myocardium, with MMP2 mRNA level 
found to be specifically higher in heart tissues 30.  
Following myocardial infarction, during remodelling, it was found that there is a type 
and region specific increase in MMPs (Fig 1.4) 31. In the infarcted region, there was a 
significantly higher level of MMP activity, especially of MMP2, 13, 8 and MT1-MMP.  
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Figure 1.4 Histogram representing regional distribution of MMPs and TIMPs after MI. 
There was a regional and type increase in MMP activity following MI. For example, in 
the MI region, levels of MMP2, MMP13, MMP8 and MT1-MMP were increased. 31. 
 
Subsequent serial assessment showed that protein level and expression of MMP2 could 
increase as early as day one following infarction, peaked at day 2 and remained 
persistently high for about 5 weeks before gradually returning to baseline (Fig 1.5) 32, 33. 
After 8 weeks post MI, there was a second surge of MMP2 protein level, but this second 
surge was not accompanied by parallel increase in its expression.  
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Figure 1.5 MMP2 mRNA and zymographic activity (left) and MMP9 zymographic 
activity (right) in infarcted (MI) rat hearts expressed as change (%) from sham-
operated hearts 33.  
 
MMP3 was also detected as early as day 2 post MI, peaked at day 4 and declined by day 
14 34 whilst MMP8 protein level increased later at day 14 post-ligation and remained 
elevated until 16 weeks post-ligation. 
Although the action of MMPs on matrix remodeling takes hours or even longer, recent 
studies indicate that there may be a more acute response, suggesting a role in acute 
pathophysiology. In isolated Langendorff perfused heart preparations, MMP2 activity 
was shown to peak at 1 minute following reperfusion after a period of global ischaemia 
(Fig 1.6) 35. The increase in activity was found to be proportional to the duration of 
ischaemia and inversely related to the recovery of the mechanical function of the heart 
(Fig 1.7).  
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Figure 1.6 Gelatinolytic activities in coronary effluent of aerobically perfused rat 
hearts and during reperfusion after ischaemia.  
A. Representative zymography showing gelatinolytic activities in coronary effluent 
during aerobic perfusion and at various reperfusion times after 20 min of global 
ischaemia. B. Densitometric analysis of specific gelatinolytic activities of pro-MMP2 
(72 kDA) and MMP2 (62 kDA) in coronary effluent samples. 35 
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Figure 1.7 Relationship between duration of ischaemia, release of pro-MMP2 and 
recovery of function during reperfusion. 
A. Representative zymogram of coronary effluent from control hearts and during the 
first min of reperfusion after 15, 20 and 25 min of global ischaemia. B. Densitometric 
analysis of gelatinolytic activities of pro-MMP2 in coronary effluents in experiments 
as in A. C. Recovery of mechanical function at 30 min of reperfusion. 35 
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When MMP2 activity was inhibited with doxycycline and 1,10-phenanthroline, there 
was an associated improved recovery of the mechanical function of the heart (Fig 1.8). 
Conversely, when semi-purified MMP was added to the perfusate, the recovery of the 
heart was worse compared to controls. 
 
 
Figure 1.8 Effects of MMP inhibition on recovery of mechanical functions expressed 
as rate-pressure product (RPP). 35 
1,10-phenanthroline and doxycycline, but not phosphoramidon (which is an inhibitor 
of metalloproteinases but without any inhibitory effects on MMPs), caused a 
significant improvement in recovery of RPP compared to controls.   
 
Subsequently, through various studies using immunohistochemistry and confocal 
microscopy, MMP2 was thought to mediate cardiac dysfunction in this setting of acute 
ischaemia-reperfusion by acting on various intracellular targets, such as troponin I, 
myosin light chain, α-actinin and titin, within the myocytes 36-38. MMP2 was found to 
co-localise with various structural and functional proteins. When incubated with these 
proteins in vitro, MMP2 was able to proteolytically cleave these proteins, and the 
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proteolysis was inhibited with addition of MMP inhibitors such as doxycycline and 
1,10-phenanthroline. The concept that ischaemia-reperfusion injury in myocytes is 
influenced by MMP2 via an independent mechanism to its actions on extracellular 
matrix is further reinforced in cell cultures and isolated myocyte studies 39, 40. Valentin 
and colleagues showed, using cell cultures, that oxidative stress increases the activation 
of MMP2 via increased expression and activation of MT1-MMP and oxidative radicals 
produced via the xanthine/xanthine oxidase complex 40. In an isolated myocyte study, 
Leon and associates showed that infusion of peroxynitrite decreased the contractility of 
the myocytes in a concentration-dependent manner, and that the effect was ameliorated 
by MMP inhibitors 39. Besides intracellular target proteins, MMP2 could generate 
reactive oxygen species (ROS) or affect the integrity of the endothelium causing 
impaired myocyte contractility 41. 
As mentioned earlier in this section, following an infarction, there was early and 
persistent increase in both protein and expression of MMP2. If a further ischaemia-
reperfusion period is induced (as occurs during elective cardiac surgery), the associated 
injury may then activate a proteolytic cascade present within the myocardium resulting 
in synergistic detrimental effects on the function of the heart. Dixon and co-workers 
examined precisely this phenomenon, with particular attention to MT1-MMP in 2 
groups of pigs 42. In the first group, the animals were subjected to LAD occlusion for 60 
min, followed by reperfusion for another 60 min (acute IR). In the second group, the 
animals first underwent surgical ligation of the circumflex artery, which is a different 
branch of the left coronary artery supplying a different territory of myocardium 
compared to the LAD. After 3 weeks, the second group of animals then underwent the 
exact same occlusion of LAD and reperfusion as the other group (acute on chronic IR). 
Haemodynamic measurements showed that at baseline (i.e prior to occlusion of LAD) 
and during ischaemia, the regional stroke work in group 2 (acute on chronic IR) was 
significantly worse compared to group 1 (acute IR) (Fig 1.9A). The activity of MT1-
MMP at baseline was also higher both at the circumflex territory (infarcted 
myocardium) as well as at the LAD territory (normal myocardium) in group 2 (Fig 
1.9B). 
 






Figure 1.9 A. Regional stroke work in pigs without and with previous MI undergoing 
IR. B. MT1-MMP fluorogenic activity at baseline (BL). 
A.Stroke work was decreased at baseline (BL) in animals with previous MI and 
remained decreased through peak ischaemia compared with animals without 
previous MI. B. In both circ (initial MI) and LAD (targeted for acute IR) regions, 
baseline MT1-MMP activity was elevated in animals with previous MI compared to 
animals without previous MI. 42 
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1.3.4 Transgenic and pharmacological inhibition studies of MMP2 in heart 
disease 
The detrimental effects of MMP2 on myocytes are reiterated in some ways in transgenic 
(knockout) and pharmacological inhibition studies. There are very few transgenic 
studies involving MMP2. Matsumura and co-workers studied wild-type (WT) and 
MMP2 knockout (KO) mice in a surgical MI model 43. After induction of surgical MI, 
the WT mice were randomised to receive either a synthetic selective MMP2 inhibitor or 
vehicle alone. During the study period of 28 days, the survival of WT mice treated with 
MMP2 inhibitor and MMP2 KO mice were significantly higher compared to WT 
control group. The main cause of death in all the mice was cardiac rupture, which 
accounted for 38.5% of the mortality. The rupture threshold of the hearts was tested at 3 
days after MI in the 3 groups and it was found that in WT control mice, the threshold 
was significantly lower by about 100 mmHg. MMP2 activity was confirmed to be 
inhibited in WT mice treated with the inhibitor and absent in the MMP2 KO group. 
ECM degradation in the groups with inhibited or absent MMP2 activity was suppressed 
compared to WT control group. In a different study, using the pressure-overload 
(induced by transaortic constriction) model, anterior and posterior wall thickness was 
significantly higher in WT mice compared to MMP2 KO mice 44. Left ventricle end-
diastolic pressure (LVEDP) was also significantly higher in the WT mice. Histology 
confirmed that myocyte hypertrophy and interstitial fibrosis induced by LV pressure 
overload were ameliorated in MMP2 KO. 
There are more data available from the literature with pharmacological MMP2 
inhibition studies to reinforce its negative role in cardiovascular diseases. Exogenous 
MMP inhibitors can be general or specific, and reversible or irreversible. A number of 
pharmacological agents have been identified that inhibit MMPs; these include 1,10-
phenanthroline, marimastat, ilomastat and doxycycline 13, 45. One potentially clinically 
useful inhibitor is doxycycline; it is the most potent inhibitor from the tetracycline class 
of broad-spectrum bacteriostatic antibiotics and its inhibitory effects are thought to 
occur independently, and at lower concentrations, to its antibacterial actions. It is the 
only drug acting as an MMP-inhibitor approved by the Food and Drug Agency (FDA) 
in clinical use as a treatment for periodontitis. Under experimental circumstances, 
doxycycline was found to inhibit MMP2 at a dose as low as 10 µM 35, 38. It is possible 
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that doxycycline decreases MMP activity by reduction of enzyme activity and RNA 
stability and inhibition of transcription in long-term inhibition. In acute inhibition, it 
inhibits MMP by its zinc-chelating action.  
In infarcted mouse hearts, at 4 days following the infarction, there is less increase in 
both the end-systolic and diastolic LV diameter at both mid-papillary and apical level 
with a broad synthetic MMP inhibitor, CP-471,474 (Fig 1.10) 46.  
 
 
Figure 1.10 Change in parameters measured with echocardiography in infarcted mice 
Day 1 to Day 4. 46 
In a longer term study, mice were examined 4 weeks after surgical induction of MI 47. 
The internal LV diameter and anterior wall thickness are preserved with MMP2 
inhibition using doxycycline (Fig 1.11).  




Figure 1.11 Representative ring segments from infarcted rat hearts in the absence (A) 
of or treated with doxycycline (B) for 4 weeks following infarction. 47 
Muscle tissues are seen as darker halftone, with scar tissue in blue.  
 
MMP2 inhibition not only preserves the LV dimensions, but it seemed to attenuate the 
progressive LV dilatation associated with post MI remodeling and reduce the expansion 
of infarct size 48. The consensus from other MMP2 inhibition studies seemed to concur 
that there is decreased acute LV remodeling, a lesser degree of change in LV 
dimensions, decreased myocardial wall stress and a lower risk of LV rupture 49-51.  
However, there are also studies of prolonged MMP inhibition that suggest it may be 
associated with adverse outcome, probably due to its interference with wound healing 
and angiogenesis 52, 53; a variety of MMP2 inhibitors, including doxycycline, were used 
in these studies. There are a few unresolved issues regarding MMP2 inhibition studies. 
The inhibitors were introduced at different time points during the protocol and the 
duration of treatment of MMP inhibitors varies between different studies. Tessone and 
co-workers started MMP inhibition day 1 post MI with subcutaneous doxycycline, with 
the treatment continuing for 9 days 53. On the other hand, Spinale and co-workers used a 
synthetic MMP inhibitor, PD200126, which was only started orally 3 days after MI and 
the treatment continued for a total of 6 months 52.   
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In the setting of acute ischaemia-reperfusion studies as discussed in Section 1.3.3, 
various MMP inhibitors used (doxycycline, 1,10-phenanthroline, PD-16673) resulted in 
amelioration of mechanical dysfunction thought to be secondary to MMP2 35, 37, 38. 
MMP2 inhibition resulted in less myocardial injury in the rat hearts subjected to isolated 
heart perfusion and ischaemia-reperfusion as demonstrated by less leakage of creatine 
kinase (CK) into the coronary effluent, as well as protecting the integrity of the 
endothelial barrier 41. The loss of intracellular target proteins of MMP2 such as α-
actinin (part of the cytoskeletal structure) was also prevented with MMP inhibition, with 
a concomitant improvement in the mechanical function of the isolated hearts 54. In 
isolated myocyte studies looking at the effects of peroxynitrite, ONOO-, on contractile 
dysfunction, it was thought that ONOO- caused contractile dysfunction via activation of 
MMP2 39. Inhibition of MMP2 delayed the onset of contractile dysfunction in the 
myocytes when exposed to ONOO-. This study using isolated and skinned myocytes 
further reinforced the concept that MMP2 exerts its detrimental effects on the hearts 
following acute ischaemia-reperfusion through a mechanism of action that is 
independent of its effects on the ECM.  
Clamping of aortic inflow line during isolated heart perfusion in the studies mentioned 
35, 37, 38, which caused global ischaemia, induced acute ischaemia-reperfusion injury 
discussed above. Such global ischaemia could occur clinically during systemic 
hypotension or may also be electively induced, as would occur during cardiac surgery. 
The duration of ischaemia determines the extent of molecular and cellular changes. 
These changes are initially reversible with full recovery of the function of the heart 55. 
However, there will be a point when reversible changes become irreversible; even with 
reperfusion, there will be little or no recovery. In coronary artery bypass graft surgery 
(CABG), post-ischaemic myocardial dysfunction may cause complications such as MI, 
severe ventricular dysfunction, heart failure and death in about 10% of patients 56.  
 
1.4 Myocardial protection and cardiac surgery  
During cardiac surgery, global ischaemia is electively induced to facilitate a bloodless 
operating field. The aims of cardioprotection during elective global ischaemia are to re-
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institute perfusion (or blood flow) to the heart as early as possible, thereby limiting the 
duration of ischaemia and to extend the duration of reversible injuries by slowing down 
the rate of development of ischaemic injury 55.  
Over the years, various ways have been used in an attempt to protect the heart during 
this period of ischaemia. The first open heart surgery in human was performed in 1953; 
this was prior to the use of the cardiopulmonary bypass machine, and used systemic 
hypothermia to protect the heart 56. In the 20 years following this landmark surgery, the 
concept of reversible chemical arrest (with the first known use of the term cardioplegia 
in 1957) was introduced in human and refined over the years. The ideal cardioplegia 
should induce rapid diastolic arrest, enhance myocardial protection, is easily reversible 
and has low toxicity 55. One of the commonest cardioplegia solutions in use clinically 
today in the UK is the St Thomas’ Hospital solution, which induces rapid diastolic 
arrest.  
There are five elements of effective cardioprotection which formed the basis for much 
of the ongoing research work in improving cardioplegia 55. Induction of rapid and 
complete diastolic arrest to reduce myocardial oxygen demand is fundamental. There 
are various mechanisms to achieve this. St Thomas’ Hospital solution induced a 
depolarised cardiac arrest by elevating extracellular potassium concentration. 
Extracellular hyperkalaemia causes depolarisation of the myocyte transmembrane 
potential 55. When membrane potential reaches about -65 mV, the voltage-dependent 
sodium channel is inactivated and thus abolished the generation of action potential, 
resulting in diastolic arrest of the heart. However, further depolarisation of membrane 
potential to around -45 mV will in turn activate the slow calcium channel leading to 
influx of calcium ions and eventually intracellular calcium overload. Hence, the 
beneficial effect of hyperkalaemia is confined to a narrow window of membrane 
potential. Yet, even within this narrow window of depolarisation, there is ongoing ionic 
imbalance due to window currents. Therefore, ongoing research is focused on other 
mechanisms to induce arrest such as polarised arrest or inhibition of calcium influx 57. 
The second way to decrease myocardial oxygen consumption is by inducing 
hypothermia. With 10°C drop in temperature, enzyme activity is decreased by about 
50% 58. However, although effective at minimising oxygen consumption, there are 
disadvantages such as ionic disturbance, alteration to microvasculature and development 
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of contracture when the temperature drops below 5°C. The third element of 
cardioprotection is to minimise the ischaemic effects with anti-ischaemic agents 55. 
Various strategies such as using blood as a vehicle of cardioplegia delivery, 
oxygenation of cardioplegia, buffering capacity of cardioplegia and additives such as 
anti-oxidants are also used. The fourth strategy is to optimise reperfusion conditions to 
maximise recovery, by reducing oxidative stress and production of free radicals. 
Supplementation with anti-oxidant enzymes and pharmacological inhibition of free 
radicals are such examples. Lastly, the vasculature, especially endothelium, and 
conducting tissues should also be protected during ischaemia to enhance post-ischaemic 
recovery of the heart.     
Despite major advances made in myocardial protection strategy, the ideal cardioplegia 
has yet to be found. There is still a high prevalence of inadequate protection during 
cardiac surgery, with myocardial stunning occurring in 20-80% of patients post-
operatively 56. If anything, in the years to come, the incidence will only increase due to 
the changing profile of patients undergoing cardiac surgery. Patients are increasingly in 
the higher risk group, with urgent or emergency surgery becoming more common, 
especially in patients with recent ACS. The search for better cardioprotection during 
surgery continues, especially as better cardioprotection not only translates to better 
immediate outcome in terms of in-hospital mortality, but it will also impact the long 
term outcome and survival after cardiac surgery 59.   
 
1.5 Acute coronary syndrome (ACS)  
Acute coronary syndrome (ACS) constitutes the largest indication for acute hospital 
admissions. Advances in diagnostic technology have enabled accurate diagnosis and 
stratification of myocardial infarction, leading to timely and appropriate reperfusion. 
However, with increased diagnostic capabilities, it also emerged that rather than a single 
entity, ACS comprises a very diverse group of patients with different risk profiles and 
outcomes (Fig 1.12) 6, 60. ACS is a spectrum of clinical conditions, ranging from frank 
ST elevation myocardial infarction (STEMI) to non-ST elevation infarction (NSTEMI) 
to unstable angina. The underlying pathophysiology in ACS was discussed in Section 
Chapter 1: Introduction 
38 
1.2. The nature and composition of the plaque and the subsequent inflammatory 
processes that follow are now thought to exert a significant contribution to the disease 
process. STEMI is usually associated with a major thrombotic event involving the 
coronary artery, where the artery is totally occluded by fibrin-rich thrombus. On the 
other hand, in NSTEMI, the coronary artery tends to be partially occluded by platelet-
rich thrombus 61. The diagnosis of ACS is established on the basis of typical clinical 
presentation, electrocardiographic evidence of ischaemia and the presence of 
biomarkers of myocardial injury 6, 62 (Fig 1.12). The early and mid-term clinical 
consequences of ACS are serious with high mortality, further ischaemic episodes and 
hospital readmission as well as other thromboembolic event such as cerebrovascular 
insults. Hence, the aim of treatment is timely reperfusion with adequate analgesia, 




Figure 1.12 Diagram illustrating the spectrum of ACS. 
ACS ranges from unstable angina to MI, with its associated biomarkers, 
electrocardiographic and haemodynamic characteristics. 6 
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In patients with STEMI, due to the complete occlusion of the coronary artery, there is a 
high risk of morbidity and mortality.  Prompt and effective reperfusion in the occluded 
vessel is the main aim of treatment 63, 64. Reperfusion in STEMI is preferably by 
primary percutaneous coronary intervention (PCI) with stents or angioplasty 65. 
However, if a hospital capable of primary PCI is not available within 60 min, then 
medical thrombolysis with clot-busting drugs such as streptokinase is the alternative 
option. Surgery is usually considered a rescue therapy if thrombolysis or PCI has failed, 
or if there are associated complications such as ruptured septum or chordae tendinae of 
the mitral valve resulting in haemodynamic compromise. Hence, surgery is best delayed 
until at least a few days after the patients are stabilised, as the associated surgical 
mortality is high 66. 
In patients with NSTEMI or even unstable angina, optimal treatment strategy remains 
an area of great debate. The cardiovascular risk in this group of patients continues with 
time as a result of further thrombotic event. Hence, the principle of treatment is to 
relieve the ischaemia and prevent further myocardial injury. There are 2 major issues to 
be resolved: the type of intervention and the timing of the intervention. Due to the 
heterogeneity of the patients, risk stratification with scoring systems remains an 
important consideration. In the newly published collaborative European Society of 
Cardiology/European Association for Cardiothoracic Surgery (ESC/EACTS) guidelines, 
the GRACE score is the preferred system 64, 67, 68. The scoring system was developed in 
1999 from the collaborative Global Registry of Acute Coronary Events (GRACE) and 
takes into account factors such as the age of the patient, the heart rate, systolic blood 
pressure, creatinine level, degree of pulmonary oedema, presence of cardiac arrest, ECG 
changes and cardiac biomarkers on hospital admission. The early invasive strategy is 
strongly recommended in high and medium risk groups, supported by Level A evidence 
64. The mode of intervention should then be dictated by the coronary anatomy, 
preferably in a multi-disciplinary setting. Hence, in some patients, urgent or emergency 
coronary artery bypass surgery may be the optimal treatment as part of the management 
of their acute coronary syndromes. Besides, despite aggressive non-surgical 
revascularisation, there may be ongoing ischaemia, or there may be other complications 
such as valvular insufficiency, ventricular septal defects or even complications 
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following PCI necessitating emergency surgery. Surgical mortality in urgent or 
emergency operation is very high, at up to 17% 69. 
In the 6th National Adult Cardiac Surgical Database Report published by the Society for 
Cardiothoracic Surgery of Great Britain and Ireland, the crude mortality in urgent or 
emergency coronary artery bypass graft surgery is 8% compared to 1% when the 
procedure is performed electively (Fig 1.13). Other surgical series have also 
demonstrated higher surgical mortality and morbidity associated with urgent coronary 




Figure 1.13 Data from the 6th National Adult Cardiac Surgical Database Report 2008. 
The crude mortality rates for isolated CABG based on urgency of the operation. 70. 
 
If the timing from MI to surgery is scrutinised further, it is obvious that surgery within 
24 hours of admission with MI is at least 3-fold higher compared to when surgery was 
carried out more than 24 hours after MI (Fig 1.14). 
 
Chapter 1: Introduction 
41 
 
Figure 1.14 Data from the 6th National Adult Cardiac Surgical Database Report 2008. 
Crude mortality rate in isolated CABG based on the timing of the most recent MI, with 
highest mortality in surgery carried out within 24 hours of MI. 70 
 
In a registry study from California, similar results were observed. The mortality was 
8.2% when surgery was performed within 24 hours of MI 71. The mortality decreased 
with increasing interval from MI to surgery to reach a low of 3% at 3 days after MI (Fig 
1.15). From the 3rd day to 7th day, there was a suggestion of slight gradual increase in 
mortality before a sharp increase in patients operated on after 14 days of MI. This 
probably represents a group of patients who were very ill and attempts made to stabilise 
the patients medically, with surgery carried out as a last resort or salvage operation. 
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Figure 1.15 CABG volume and mortality over time 
Distribution of CABG volume (left y-axis, no of cases/day) and % mortality (right y-
axis) per day of hospitalisation. Dashed horizontal line represents total mortality over 
the study period (4.8%). 71 
 
Although these reports use crude mortality rates and are not from randomised controlled 
studies, it provides a snapshot of the experience in cardiac units in a realistic setting. 
The pathophysiology of acute ischaemia-reperfusion injury, either regional acute 
myocardial infarction or global ischaemia as electively induced during cardiac surgery, 
has been studied extensively both at the cellular and molecular level 55, 72. As a result, 
various therapeutic interventions, such as cardioprotection during cardiac surgery as 
discussed in Section 1.4, have greatly enhanced and improved the clinical management 
and outcome of these patients. However, regional ischaemia followed rapidly by global 
ischaemia is rarely studied together in the experimental setting, although it is likely that 
acute regional ischaemia and subsequent global ischaemia will result in greater 
myocardial dysfunction than either situation on its own, despite the cardioprotective 
techniques that can be incorporated during cardiac surgery. Clinically, this scenario is 
clearly depicted by patients with acute myocardial infarction, which results in acute 
ischaemia of the territory supplied by the coronary artery involved, who subsequently 
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undergo urgent coronary artery bypass surgery, when their myocardium is subjected to 
further global ischaemia. An initial ischaemia may result in upregulation of bioactive 
molecules, with a consequent activation of various proteolytic pathways and proteases 
73-75. The upregulation of these bioactive molecules may occur even in the region remote 
to the infarcted or ischaemic zones. The pathways are then primed to respond when a 
second ischaemia-reperfusion injury occurs such that the resultant left ventricular 
dysfunction is exacerbated 42. There are many factors that are involved in the 
pathophysiology of myocardial ischaemic injury; these include mitochondrial 
dysfunction leading to increased oxidative stress, reduced contractility associated with 
dysfunction of the sarcoplasmic reticulum Ca2+-ATPase and cellular and mitochondrial 
ionic changes 76. There is also increasing evidence that extracellular matrix degradation 
is involved in cardiac dysfunction associated with myocardial ischaemia 77, 78.  
Since the seminal discovery of MMPs by Gross and Lapiere 9, 12, research into the 
various biological and pathological roles of MMPs has rapidly expanded over the 
decades. In cardiovascular diseases, it has become clear that MMPs, especially MMP2, 
play a significant role not only in long term remodeling processes, but they are also very 
much involved as key players in acute processes such as ischaemia-reperfusion.  
There is an emerging and significant clinical scenario of patients with acute coronary 
syndrome, who may require urgent cardiac surgery within one week of the onset of 
ACS. There is currently ongoing debate about the optimal revascularisation strategy in 
this group of patients. As mentioned earlier, the morbidity and mortality in this group of 
patients are invariably higher. Ongoing research into better cardioprotection for this 
group of patients is required to improve the outcome. Even in elective cardiac surgery, 
with a much lower mortality, current cardioprotection with cardioplegia during surgery 
is not optimal. The heart is still subjected to oxidative stress with inadequate protection 
of tissues such as the microvasculature. The role of MMP2 in this circumstance has not 
been established, although there is supporting evidence that link MMP2 with oxidative 
stress 79 and that MMP2 regulates vascular tone, and has both vasodilatory and 
vascoconstrictive effects 13. MMP2 inhibition during cardiac surgery may provide an 
additional adjunct in protection of myocardium, optimisation of reperfusion condition 
by reducing the effects of oxidative stress and protection of the endothelium of coronary 
vasculature. 
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1.6 Hypothesis, aims and objectives 
We hypothesise that increased matrix metalloproteinase (MMP) activity, induced by an 
acute ischaemia-reperfusion event in the heart, is associated with the resultant cardiac 
dysfunction. Since cardiac surgery imposes an additional ischaemia-reperfusion burden, 
effects of MMP activity will be exacerbated. Cardioplegia protection, with or without 
MMP inhibition will improve post-ischaemic cardiac function. 
The aims of this study are to elucidate the role of MMP2, in a laboratory setting, where 
regional infarction is initially induced in laboratory rat hearts, and subsequently after a 
week, the infarcted hearts are then subjected to global ischaemia, as would occur during 
cardiac surgery. The isolated Langendorff perfusion model would be used as a model to 
study the effects of global ischaemia. This, we hope, will contribute towards improving 
cardioprotection in patients undergoing cardiac surgery after acute coronary events.  
Our specific objectives are therefore to determine: 
1. What is the additional effect of global ischaemia-reperfusion on the infarcted 
hearts, as would occur during cardiac surgery? 
2. What is the profile of MMP2 activity in the infarcted hearts during the additional 
global ischaemia-reperfusion during isolated heart perfusion? 
3. What is the influence of cardioplegia protection (with or without inhibitors of 
MMP) during the global elective ischaemia-reperfusion on the mechanical 
function of the heart? 
4. What is the optimal timing for the administration of MMP2 inhibitors post-
myocardial infarction to achieve the maximal benefit? 
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2 GENERAL METHODS 
The general experimental techniques used in the studies are described in this chapter. 
Where there were specific alterations to the standard technique or if the method was 
only used once, it is described in detail in the relevant chapters. Specific protocols 
pertaining to certain studies are also described in the relevant chapters. The animals 
used in these studies were adult (10-week old), male Wistar rats, weighing between 250 
to 350 g in body weight. All animal experiments were performed in accordance with the 
United Kingdom Home Office Guidance on the Operation of Animals (Scientific 
Procedures) Act 1986, published by Her Majesty’s Stationery Office.  
 
2.1 Surgery and anaesthesia 
Animal experiments were performed in keeping with the standards and conditions set 
out by King’s College London and the Home Office Animals Scientific Procedure Act 
(1986). All proposed procedures and protocols were also discussed with the veterinarian 
prior to commencement. All procedures carried out were included within the schedule 
of my personal license (PIL 70/22124) and the departmental project licences (PPL 
70/6446 and PPL 70/6635).  
Rats were housed in the Biological Services Unit (BSU) on site and within the Waterloo 
campus of King’s College London. The ambient temperature was maintained at 24°C, 
with 55-65% relative humidity, 12-hour alternating light-dark cycle and with free access 
to food and water. Recovery surgery and anaesthesia were performed within a dedicated 
procedure room in the BSU at the Waterloo campus, with strict asepsis. The animals 
were recovered for 7 days prior to isolated Langendorff heart perfusion studies.  
2.1.1 General anaesthesia 
Recovery surgery and procedures were performed under inhalational anaesthesia with 
isoflurane. Isoflurane is a volatile halogenated agent, which has a more favourable 
cardiovascular profile compared to other anaesthetic agents, with less myocardial 
sensitisation to endogenous catecholamines and other related compounds 80. 
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Furthermore, recovery of the animal is faster with isoflurane. Isoflurane was delivered 
in 100% oxygen at a flow rate of 3 L/min via a vaporiser. Induction of anaesthesia was 
carried out by placing the rat in an induction chamber and then transferring to an 
operating table with a homeothermic plate, using an open circuit system with a nose-
cone (fashioned from a 10 ml syringe). Where thoracotomy was required, invasive 
ventilation was then used with endotracheal intubation as described below. 
The depth of anaesthesia was determined by assessing respiratory rate and nociception 
with toe pinching. Intervention was only carried out once these reflexes were abolished.  
2.1.2 Invasive mechanical ventilation with endotracheal intubation 
There are various ways described by different principal investigators within our 
department regarding endotracheal intubation of rodents. Essentially, it could be either 
direct vision of the vocal cords using a paediatric laryngoscope or surgical dissection of 
the trachea to visualise the endotracheal tube in the trachea directly. After long 
consideration, given the instruments that were readily available, with the position of the 
animal to optimise surgical procedure, I decided that surgical dissection of the neck to 
visualise the endotracheal tube was best suited for this project. Intubating with a 
laryngoscope would require the animal to be positioned initially with the head towards 
the operator, and subsequently changing the position of the animal for the surgical 
procedure. This was not logistically feasible given the way the anaesthetic circuit is set 
up on the operating table.  
With the animal placed supine on the operating table, ventilated with the nose-cone 
system, dissection was carried out to expose the trachea. The larynx is bordered by the 
epiglottis ventrally, aryepiglottis laterally and arytenoid cartilage dorsally. The wall of 
the laryngeal vestibule is flexible. The glottis is bounded by elastic vocal ligament and 
rigid cricoarytenoid ligament 81. The elastic epiglottis is shaped like a grooved 
triangular leaf in a straight caudal base and long apex. Pointed and curved cuneiform 
processes arise near the base laterally.  
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A small vertical incision was made in the midline in the neck. The subcutaneous tissue 
was dissected to expose sternohyoideus muscle, which was separated and retracted to 
expose the trachea (Fig 2.1). With the rat supine, the tongue was gently retracted with a 
pair of forceps to open the epiglottis. 
 
 
Figure 2.1 Superficial and deep anatomy of the neck of a rat 81 
 
An endotracheal tube (ETT) (which was fashioned using a 14G cannula) was then 
gently advanced endotracheally and under direct vision into the trachea (Fig 2.2).  The 
position of the ETT was maintained at just above the carina. This is to prevent injury to 
the carina, which may result in tension pneumothorax, causing the death of the animal 
shortly after surgery. The 14G cannula formed a reasonably tight seal with the trachea 
to allow satisfactory ventilation. The animal was ventilated using the 7025 rodent 
ventilator (Ugo Basile) with a respiratory rate of 50, and tidal volume of 2 ml.  
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Figure 2.2 Insertion of ETT under direct vision. 
The neck incision was retracted to expose the trachea. Under direct vision, the ETT 
was inserted into the trachea. 
 
At the end of the surgical procedure, it is important to ensure adequate expansion of the 
lungs to optimise recovery of the rat. This was achieved by increasing the tidal volume 
to 3-4 ml with positive end expiratory pressure (by submerging the efferent tubing of 
the exhaust port in water). Isoflurane was discontinued and ventilation maintained with 
100% oxygen. The respiratory rate was gradually decreased to 35-40 breaths/min until 
spontaneous ventilation resumed and nociceptive reflexes restored, at which point the 
animal was extubated. The animal was then recovered in a hot-box at 24°C overnight.  
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2.1.3 Anterior thoracotomy and ligation of left anterior descending (LAD) 
artery 
Prior to performing the surgical procedure, it was essential to understand the anatomy of 
the coronary arteries, particularly the left coronary artery, in the rodents. The left 
coronary artery originates from the aorta, in contact with the left margin of the 
pulmonary cone, at about 1 mm from the insertion of the left atrial appendage (Fig 2.3) 
82. The left coronary artery is predominant and supplies the left ventricle. The coronary 
artery lies beneath the epicardium, buried in the myocytes. Hence, it is important to 
ensure the sutures are placed at an adequate depth to ligate the LAD effectively 83.  
 
Figure 2.3 Anterior aspect of a rat heart. The coronary arteries of the heart were 
injected with lead oxide in latex (Picture 1). In Picture 2, a curved needle had been 
introduced between the pulmonary cone and the insertion of the left atrial 
appendage, to demonstrate the position for occlusion of LAD. Additional ligatures 
were also shown in the picture to show alternative positions to place the ligature 
more distally along the LAD, to produce smaller infarct if needed. 82 
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In order to learn and master the technique of LAD ligation, time was spent discussing 
the technique with various experts and by observing the way the procedure was carried 
out in murines. The initial technique used was a result of the various discussions with 
modification from that observed in murines. 
The final technique was modified after careful study of Selye’s description of that used 
for surgical occlusion of coronary vessels in rat 82. Once the animal was anaesthetised, 
the animal was secured on the homeothermic plate to maintain the core body 
temperature at 37°C (ADinstruments ML295/R). The fur from the thorax was then 
clipped with an electric shaver. Betadine was used to sterilise the thorax and surgery 
was performed using full aseptic technique. Clean and sterile drapes were used to cover 
the abdomen and on the side to provide a sterile operating field. A lateral skin incision 
along the ribs was made, starting just below the lower border of the forelimb, from the 
left mid-axillary line to just slightly to the right of the sternum. This was modified from 
the original technique described; Selye described a midline incision along the sternum, 
but lateral skin incision provided better access. The pectoralis muscle was then divided 
to the sternal attachment to reveal the sternum and intercostal muscle. At this stage, the 
respiratory rate is decreased down to 25-30 and tidal volume decreased to about 1 ml to 
visualise the beating heart so that the optimal intercostal space was used to enter the 
pleural cavity. Blunt scissors were used to carefully dissect the intercostal muscles, 
about 1 mm from the sternal edge to puncture the pleura (Fig 2.4). This avoids 
dissecting the internal mammary artery that runs along the sternum, which may result in 
massive haemorrhage. Respiratory rate and tidal volume were kept at a minimum to 
decrease the likelihood of injury to the lungs during puncture of the pleura. Once the 
pleural cavity was entered, the incision was widened gradually with the scissors. The 
pleura was carefully incised laterally to improve access to the heart. Carefully, the rib 
was cut using sharp scissors about 1.5 mm from the sternal edge. Haemostasis was 
achieved using electrocautery as the intercostal bundle would be invariably cut. Using 
electrocautery, it was possible to minimise the amount of bleeding. The incision was 
widened by dividing the intercostal muscles below this rib. 
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Figure 2.4 Anterior thoracotomy to expose the heart. 
Lateral skin incison to expose underlying pectoralis muscle, which was separated 
and blunt dissection was carried out to enter the pleural cavity. The left lung was 
visible in this view. 
 
Next, the pericardium was carefully perforated to visualise the heart. A pair of forceps 
was used to steady the cut sternal edge of the rib and, with the blunt end of another pair 
of forceps in the pericardial cavity, the heart was exteriorised with pressure on the right 
thorax (Fig 2.5). Once the heart was exteriorised, a suture was placed between the point 
of entry on the left margin of the pulmonary cone and the middle of an imaginary line 
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connecting this point with the closest point on the insertion line of the left atrial 
appendage. The suture used was 5/0 prolene with blunt needle.  
 
Figure 2.5 Exteriorisation of the heart 
The heart was exteriorised to enable placement of LAD suture safely. 
Once the suture was placed, the heart was returned to the thorax before tying the suture. 
This was to ensure that the duration the haemodynamics of the heart were affected by 
the position of the heart outside the chest was as short as possible. When the suture was 
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tightened, there was visible evidence of ischaemia as the myocardium turned pale. 
Haemostasis was then achieved. 5/0 prolene was used to approximate the ribs together. 
The respiratory rate and tidal volume were restored back to 50 breaths/min and 3 - 4 ml 
mentioned previously. Positive end expiratory pressure (PEEP) of 1 cm water was also 
applied at this stage to ensure adequate lung expansion prior to approximating the ribs. 
Once the ribs were approximated, the PEEP was removed and tidal volume decreased 
back to 2 ml. The divided muscles were then approximated and during the process, 
intermittent pressure on the left thorax was applied to expel any residual air. The skin 
incision was closed with 5/0 prolene. Betadine was used to clean the wound prior to 
skin closure. 
Normal saline (2 ml) and analgesia (vetergesic 0.2 mg/kg) were given to the animal 
intraperitoneally during recovery. Isoflurane was switched off and the animal extubated 
once spontaneous respiration resumed. The animal was then recovered in a hot-box at 
temperatures between 24°C to 28°C overnight with free access to food and water.  
 
2.2 Isolated Langendorff heart perfusion system 
The rat was anaesthetised with 0.8 -1.0 mls of 30% pentobarbitone (diluted in 0.9% 
saline) intraperitoneally. Once the animal was in deep anaesthesia, determined by the 
loss of pain reflex to toe-pinching, 0.1 ml of 1,000 U/ml of heparin was injected into the 
femoral vein.  
Scissors were used to make a clamshell incision across the chest, with division of the 
diaphragm to expose the mediastinum. The heart was then rapidly excised and 
immersed in cold Kreb-Henseleit solution. The aorta was then cannulated on the 
Langendorff set-up and secured using 3/0 silk suture. The heart was cannulated within 
30 s of excision. Once cannulated, the heart was retrogradely perfused with Kreb-
Henseleit buffer (composition in mM: NaCl, 118.5; NaHCO3, 25.0; KCl, 4.75; MgSO4, 
1.19; KH2PO4, 1.18; Glucose, 11.0 and CaCl2 1.4) at 100 cm H2O at 37°C, continually 
gassed with a mixture of 95% oxygen:5% carbon dioxide. The suspended heart was also 
immersed in a warm fluid bath to maintain the temperature at 37°C (Fig 2.6). 
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An incision was then made to the left atrium and a water-filled balloon (which was 
fashioned from clingfilm to fit the left ventricle) was inserted through the mitral valve 
into the left ventricle 84. The balloon was connected to a pressure transducer, which 
allows real-time measurement of the mechanical function of the heart. The balloon was 
inflated to achieve an end-diastolic pressure of 5-10 mmHg. The heart rate, left 
ventricular systolic pressure (LVSP) and end-diastolic pressure (LVEDP) was 
monitored and acquired continuously and stored using LabChart 7. The left ventricular 
developed pressure (LVDP) was determined by LVSP minus LVEDP. The heart was 
allowed to stabilise for 20 minutes before starting the experimental protocol. Exclusion 
criteria were applied during this equilibration period; any hearts that did not achieve a 
LVDP of ≥100 mmHg, or if the coronary flow (CF) was ≥20 ml/min (implying a leak 
within the perfusion system) or ≤6 ml/min (implying a perfusion problem) were 
excluded. 
 
Figure 2.6 Schematic diagram of the isolated Langendorff heart perfusion, constant 
pressure system. 
All parts of the perfusion hardware are water-jacketed with warm circulating water to 
maintain constant temperature 85. 
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A second reservoir attached to the side-arm of the perfusion rig allowed any 
experimental drug to be administered to the heart. Global ischaemia was induced by 
clamping the aortic in-flow line. Occasionally, during reperfusion, the heart may 
develop ventricular fibrillation. If this happened, the heart was defibrillated back to 
sinus rhythm.  
 
2.3 Extraction of proteins from rat heart tissue 
With any ex vivo assays of MMP2 activity, sample preparation is crucial. Care was 
taken to avoid adding reagents that could alter endogenous MMP activity such as 
common reducing agents (e.g ethylenediaminetetraacetic acid, EDTA, and 
dithiothreitol, DTT). Hence, some advocate avoidance of such compounds in extraction 
buffers 86. On the other hand, without reagents such as DTT, the extraction process may 
not be adequate to yield sufficient proteins for analysis. This may explain why most 
studies were carried out with a small amount of such reagents 35, 37, 79. Therefore, it was 
crucial to first of all determine the optimal composition of extraction buffer for use 
throughout these studies.  
At the end of the isolated Langendorff perfusion protocol, hearts were freeze-clamped 
in liquid nitrogen, the heart samples were ground into a powder form in liquid nitrogen 
using a mortar and pestle, and subsequently stored at -80°C until use.  
A sample of powderised heart (50 mg) was used with 150 µl of lysis buffer; 2 different 
lysis buffers were tested initially. A total of 30 heart tissue homogenates were used with 
buffer A and 42 with buffer B. 
Composition of lysis buffer A (in mM): 
β-glycerophosphate 20, sodium fluoride 50, benzamidine 10, sodium orthovanadate 0.2, 
Triton X-100 1%, Complete protease inhibitor tablet (Roche) 
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Composition of lysis buffer B (in mM): 
β-glycerophosphate 20, sodium fluoride 50, benzamidine 10, sodium orthovanadate 0.2, 
DTT 1, Triton X-100 1%, Complete protease inhibitor tablet (Roche) 
The samples were mixed with ice-cold buffer in 1.5 ml eppendorf tubes. A micropestle 
was used to mix and break down the tissues. The sample was then vortex mixed to 
allow thorough mixing. After about 5 min to allow for the extraction process, the 
samples were centrifuged at 10,000 rpm at 4°C for 10 min. The supernatant was 
collected for use in the Bradford assay to determine its protein content. The Bradford 
assay is described in Section 2.4. The mean protein concentration in the supernatant 
from the different buffers was compared using Student’s t-test.  A value of p<0.05 was 
considered statistically significant.  
The mean protein concentration (µg/µl) when buffer A was used was 2.3±0.1 (95% CI 
1.8-2.7), which was significantly (p<0.0001) lower than the equivalent extraction 
concentration of 22.0±0.8 (95% CI 18.7-24.4) when buffer B was used (Fig 2.7). This 
showed that a reducing agent, which linearises the protein structure making it easier for 
extraction, is required to improve protein extraction from tissues. Hence, in subsequent 
analysis, lysis buffer B was used for homogenisation of the hearts.  
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Figure 2.7 Graph showing the distribution of the concentration of proteins extracted 
using lysis buffers without (buffer A) and with (buffer B) DTT. 
 
2.4 Bradford protein assay 
The Bradford protein assay was carried out after extraction of proteins from the heart 
homogenates to determine the concentration of the protein in the samples. This allows 
for an equal amount of protein loading with the various molecular assays. The Bradford 
dye assay is based on the equilibrium between three forms of Coomassie Blue G dye, 
and gives a relatively stable colorimetric response compared to other methods.  
The dye solution was prepared by dissolving 50 mg of Coomassie Blue G250 in 50 ml 
of methanol. The solution is then added to 100 ml of 85% hydrophosphoric acid, and 
further diluted with 500 ml of distilled water. The solution was then filtered to remove 
any precipitates. After filtration, another 350 ml of distilled water was added to the final 
solution. This solution was stored in a dark bottle at 4°C as it remains indefinitely stable 
in this condition.  
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Protein standards were prepared using bovine serum albumin (BSA). Nine standards 
containing 0, 1, 2, 4, 6, 8, 10, 12 and 15 µg/ml of BSA were made. One ml of dye 
solution was added to the standards and samples to be assayed and mixed with the 
whirlmixer. The solution was allowed to equilibrate for a few minutes before recording 
the absorbance at 595 nm using a spectrophotometer. The absorbance of the protein 
standards was used to plot a standard curve and the standard curve used to determine the 
concentration of the samples (Fig 2.8).  
 
Figure 2.8 An example of a standard curve obtained with Bradford protein assay. 
 
2.5 Protein immunoblot (Western blot) 
Western blot is an analytical technique that is widely used to detect specific proteins in 
a given tissue sample. It is based on the principles of electrophoresis to separate proteins 
by their molecular weight. The proteins are then transferred to a membrane to be probed 
using antibodies specific to the target proteins. 
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2.5.1 Preparation of samples 
1. The sample of tissue homogenate was mixed in sample buffer made up with  
40% v/v glycerol,  8% w/v sodium dodecyl sulphate (SDS),  0.25 mM Tris,  
10% v/v 2-mercaptoethanol and 8% w/v bromophenol blue. 
2. 4X sample buffer was used to minimise dilution of the samples. 120 µl of tissue 
homogenate was added to 40 µl 4X sample buffer. 
3. The tissue homogenate in the sample buffer was boiled at 100°C for 5 minutes. 
The boiling, together with the SDS in the sample buffer will denature and reduce 
the proteins. The boiled samples were then centrifuged in 4°C at 10,000 rpm for 
5 minutes. 
4. 50 µg of the proteins (as determined by Bradford assay) was loaded onto the 
wells.  
2.5.2 Electrophoresis and transfer of proteins 
1. 8% acrylamide gels were used as the molecular weight of proMMP2 is 72 kDa. 
Activated and proteolytically-cleaved MMP2 has a molecular weight of 62 kDa. 
Polyacrylamide gels, which consists of a lower resolving gel (8% acrylamide 
gel) and an upper stacking gel (6% acrylamide gel) were set between glass 
plates, separated by 1 mm spacers. The compositions of the gels are listed in 
Table 2.1.  Samples were loaded into wells created by the insertion of a plastic 
toothed comb (10 wells) into the stacking gels during preparation of the gels. 
Table 2.1 Composition of stacking and resolving gels  
Resolving gel Stacking gel 
0.375 mM Tris pH 8.8 125 mM Tris pH 6.8 
0.1% SDS 0.1% SDS 
8% acrylamide 6% acrylamide 
0.1% tetramethylethylenediamine  
(TEMED) 
0.1% TEMED 
0.15% ammonium persulphate (APS) 0.15% APS 
 
2. A standard running buffer of 1X Tris-glycine was used. 
3. Separation of the proteins was carried out using Mini Protean III gel 
electrophoresis system (Bio-Rad, UK) at 200V for about 30-45 min, or until the 
dye over-runs the gel at the bottom.  
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4. The proteins were transferred using electroblotting to expose it on a thin surface 
layer for detection. A semi-dry transfer system  (Bio-Rad, UK) was used. 
5. Polyvinylidene difluoride membrane (PVDF) (Hybond P; GE Healthcare, 
Amersham, UK) was used because of its non-specific protein-binding properties 
(via hydrophobic and charged interactions between proteins and membrane).  
6. The PVDF membrane was cut to size and pre-soaked in methanol prior to use. 
7. The PVDF membrane was sandwiched with the resolving gel between pre-
soaked (in transfer buffer) Whatman electrode papers. 
8. The transfer buffer was made up of 25 mM Tris, 150 mM glycine and 20% 
methanol. SDS was not used in the buffer as the molecular weight of MMP2 is 
<100.  
9. The sandwich of paper/PVDF/gel/paper was then placed between the electrodes, 
with the membrane closest to the positive electrode and the gel closest to the 
negative electrode. Care was taken to ensure the system was well-lubricated with 
transfer buffer and free of air bubbles to increase the effectiveness of the 
transfer.  
10. The set up is then run at 20V for 120 min.  
2.5.3 Blocking and incubation with antibodies 
1. Following transfer, the membrane was blocked to prevent non-specific binding 
of proteins in order to reduce background signal.  
2. The membrane was blocked using 5% skimmed milk made up in Tris Buffer 
Saline Tween 20 (TBST). It was left on an agitator at room temperature for 1 
hour. 
3. Incubation with primary antibody was then carried out overnight at 4°C on an 
agitator. The primary antibody (rabbit polyclonal H-76, Santa Cruz) was diluted 
1:200 in TBST.  
4. The following day, the membrane was washed 6 x 5 min in TBST at room 
temperature on an agitator.  
5. The secondary antibody (donkey anti-rabbit, Santa Cruz) was then incubated for 
2 hours at room temperature on an agitator. The dilution used was 1:5,000 in 
TBST.  
6. After 2 hours, the membrane was again washed 6 x 5 min in TBST.  
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2.5.4 Detection 
1. As the antibody used is horseradish peroxidase (HRP)-conjugated, enhanced 
chemiluminescence (ECL) detection kit is used. The reagents were mixed and 
allowed to equilibrate with the membrane for 2 min at room temperature. 
2. The X-ray films were then developed manually in a dark room with variable 
exposure times. 
 
2.6 Substrate (gelatin) zymography 
The most widely used and conventional method to assess MMP activity is substrate 
zymography. This is an electrophoretic technique based on SDS-PAGE, where the 
substrate is co-polymerised with the polyacrylamide gel. Hence, the detection of MMP 
activity is based on molecular weight separation. It is relatively cheap, sensitive, widely 
used (hence allowing comparison with other studies) and is a good screening tool. 
Sample preparation and tissue extraction is a very critical step in substrate zymography 
86, 87. This is especially true in tissues; the amount of MMPs in tissue is about 50-fold 
less than that present in culture media, and difficult to extract due to tight binding of 
MMPs to extracellular matrix. Disruption of the tissues during the extraction process 
may cause binding of MMPs to its respective inhibitors, which in an intact tissue are 
localised in distinct compartments. This could potentially lead to inactivation of MMPs. 
It is important to exclude reducing agents such as EDTA and zinc-chelators from the 
homogenisation buffer 86. Additionally, the samples should not be boiled as boiling 
could activate the enzymes.   
2.6.1 Ingredients 
The composition of the gels and buffers used in zymography are shown in Tables 2.2, 
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Table 2.2 Composition of gelatin and stacking gel 
0.1% Gelatin Gel Stacking gel 
8% acrylamide 
0.1% Gelatin 











Table 2.3 Composition of non-reducing loading, renaturation and developing buffers 
Non-reducing  
Loading buffer 
Renaturation buffer Developing buffer 
0.25 mM Tris pH 6.8 
40% v/v glycerol 
8% w/v SDS 
8% w/v bromophenol blue 
water 
2.5 M NaCl 
Triton X-100 
water 
1 M Tris pH 7.4 
2.5 M NaCl 
1 M CaCl2 
10 mM ZnCl2 
water 
 
Table 2.4 Composition of stain and destain solutions 
Stain solution Destain solution 
25% v/v Methanol 
7% v/v Acetic acid 
2.5% w/v Coomassie Blue R250 
water 
25% v/v Methanol 




Chapter 2: General Methods 
63 
2.6.2 Gel preparation 
1. All apparatus was washed and cleaned with 70% ethanol.  
2. The ingredients for the running gels (8% gel) were mixed together in a 50 ml 
Falcon tube. It was mixed together gently to ensure the least amount of air was 
mixed in as oxygen inhibits the polymerisation process.  
3. The running gel was then pipetted into the western blot glass plates, and usually 
takes about 30 min to set. A small amount of butanol was applied to the top of 
the gel to ensure no air bubble was trapped. When the gel set, the butanol was 
washed off with distilled water.  
4. The ingredients for stacking gel were mixed together and applied carefully to the 
top of the running gel. The comb was carefully and quickly slid on top of the 
gel, ensuring no air bubbles were trapped in the comb.  
 
2.6.3 Electrophoresis and incubation with developing buffer 
1. The running buffer used is cold SDS/Glycine/Tris. 
2. Samples or 0.34 ng of MMP2 standard (Calbiochem) was loaded onto the wells.  
3. Electrophoresis of the gels was carried out surrounded by ice, with a constant 
voltage of 90 V. It was allowed to run until the dye over-runs the gel at the 
bottom; this was generally about 150 min.  
4. After electrophoresis, the gel was removed from the plates and stacking gel 
trimmed off.  
5. The gel was rinsed in water for about 10s. 
6. The gel was then incubated in renaturation buffer 2x30 min. 
7. It was then incubated in developing buffer at 37°C for about 36 hours.  
8. The following day, after washing the gels twice in water, it was stained in the 
staining solution for 2 hours at room temperature on an agitator. 
9. Subsequently, it was destained in the destaining solution for 4 hours at room 
temperature on the agitator.  
10. The gel was then scanned using GenSnap software.  
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2.7 MMP2 activity assay 
The hearts were homogenised with β-glycerophosphate buffer as previously described 
in Section 2.3.  
The MMP2 activity assay kit was purchased from GE Healthcare; it is specific for 
MMP2 and allows a precise quantification of active and pro-MMP2. The range of active 
MMP2 measured, with a longer incubation period, is 0.19-3.0 ng/ml, with a sensitivity 
of 190 pg/ml. The assay uses a pro-form of a detection enzyme, which can be activated 
by captured active MMP2, through a proteolytic event (Fig 2.9).  
 
 
Figure 2.9 Protocol for measuring MMP2 activity 
The activated detection enzyme was then measured using a specific peptide substrate. 
The kit consisted of a 96-well plate coated with anti-MMP2. All assays were carried out 
in duplicates. The buffers were made up as per instructions in the booklet. A set of 12 
working standards, ranging from 0.19 to 12 ng/ml, was prepared. 100 µl of standards 
and samples were pipetted into the wells. The unknown samples and working standard 
were incubated overnight at between 2-4°C. Any MMP2 present in the samples was 
captured in the well. The next day, the wells were washed 4 times before adding the 
detection enzymes. The optical density (OD) of the plate was read at 405 nm in a 
microplate spectrophotometer to obtain a t=0 value. The plate was then covered and 
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incubated at 37°C for 6 hours. Another value for OD was read after the incubation time. 
A standard curve was constructed, and the concentration of MMP2 in the samples 
extrapolated from the curve (Fig 2.10). 
 
Figure 2.10 Typical standard curve for a 6-hour incubation period 
Assays were carried out using old and fresh DMSO. With a preliminary study that was 
carried out when I first used the assay, the standard curve obtained was very different 
from what I should expect according to the manual. Following discussion with the 
manufacturer, the reason for that could be due to DMSO, which was used as a solvent 
for p-aminophenylmercuric acetate (APMA). APMA was used in the assay to activate 
MMP2 in the standard. Although a stable compound, when exposed to room air, DMSO 
will self-dilute to about 66% as it is extremely hygroscopic. Hence, I wanted to 
ascertain if there was a difference in the assay results when DMSO, that had been 
opened for more than a year and sitting on the laboratory shelf (old), was used 
compared to newly bought (fresh) DMSO. Additionally, I also wanted to test the shelf 
life of the kit. According to the instructions from the manufacturers, once the 
components were constituted, and if stored according to instructions, i.e buffers at 4°C 
and reagents at -20°C, the kit should be reusable for a 4-week period. Hence, standard 
curves were constructed using the same kit at 2 different intervals – in one pair of 
standard curves, an interval of 10 days was used; subsequently, using another set, the 
curves were constructed 4 days apart. 
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Firstly, the comparison of the standard curve using old and fresh DMSO as a solvent for 







Figure 2.11 Standard curves obtained with MMP2 activity assay. 
The standard curves obtained using MMP2 activity assay (i) expected curve 
reconstructed from the values given in product booklet, (ii) standard curve obtained 
using old DMSO and (iii) standard curve obtained using fresh DMSO. 
As can be seen from the curve obtained, fresh DMSO was crucial to obtain a standard 
curve that approximated the expected standard curve as given in the product booklet.  
The standard curves obtained from the same kit were different when the assay was 
performed on different days. The curves obtained are shown in Fig 2.12; standard 
curves obtained 10 days apart showed that the curve approximated to using old DMSO, 
hence giving a very low standard curve. The effect was less pronounced when the 
assays were performed only 4 days apart.  













Figure 2.12 Various standard curves obtained using MMP2 activity assay under 
different conditions. 
(i) Expected standard curve, replotted using values given in product booklet. (ii) and 
(iii) were standard curves obtained from the same kit, but the assay performed 10 
days apart. (iv) and (v) were standard curves obtained from the same kit, but assay 
carried out 4 days apart. 
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Subsequently, I compared the standard curves obtained using fresh DMSO, from two 
separate MMP2 activity assay kits that were newly opened, arbitrarily labelled Assay 1 
and Assay 2. Both assays were carried out with strict adherence to the conditions 
instructed by the manufacturer. The slopes of the curves obtained were compared using 
linear regression and showed significant (p=0.001) differences (Fig 2.13).  
 
Figure 2.13 Linear regression of standard curves obtained using 2 different MMP2 
activity assay kits. The assays were carried out on different days, with 2 separate 
kits. 
 
In conclusion, it is very important to use fresh DMSO in this assay and preferably the 
whole plate should be used at one go, and fresh from the package. Given the variability 
in the standard curve, the quantitative qualities of the kit should be interpreted with 
caution. It may be more accurate to draw a conclusion on the trend obtained. Caution 
should also be exercised in trying to interpret results from different plates (performed at 
different times) as it may not be conclusive. However, although the MMP2 activity 
assay has its disadvantages (illustrated here), my opinion is that it is still the better 
assay; it is readily available in the laboratory, relatively easy to perform, and measures 
directly activity of MMP2s more accurately as the assay is independent of the molecular 
weights of MMP2.  
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2.8 Statistical analysis 
Statistical analyses were carried out using Prism v5.0f software (GraphPad, USA). All 
values were expressed as mean±SEM. Comparisons of means of data sets between 2 
groups were carried out using unpaired or paired t-test as appropriate. Comparisons of 
means of multiple data sets were carried out using one-way analysis of variance 
(ANOVA) with appropriate post-hoc tests for multiple comparisons. Specific statistical 
analysis is described in the Results chapters as appropriate. 
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3 PRELIMINARY STUDIES TO DETERMINE THE 
EXPERIMENTAL DESIGN 
3.1 Introduction 
The aims and objectives in this study, as mentioned in Chapter 1, section 1.6, were to 
study the role of MMP2 and mechanical dysfunction in the infarcted heart when 
subsequently subjected to an additional global ischaemic burden. This mimics closely 
the group of patients presenting with ACS and undergoing CABG within a short 
interval from their ACS.  
In the past, experimental surgical occlusion of the coronary circulation was popular in 
dogs to study the consequences of myocardial infarction, due to the similarities in the 
coronary circulation between human and dogs. Although dogs are convenient animals to 
perform thoracotomy on, unfortunately, because of their collateral circulation, they are 
an unreliable animal to use to achieve consistent infarct areas or survival of the animal 
post-surgery 83, 88. The resultant infarct size may be minimal due to the collateral 
circulation or the dogs will not survive post-ligation as a consequence of a large infarct 
(Fig 3.1). Hence, this caused difficulty in reproducing the results and failure to replicate 
the laboratory findings in clinical trials. Attention was then turned to other animals, 
especially small animals, in an effort to either develop a more reliable model or have 
larger study numbers to achieve statistical significance. Rats were shown to be a good 
small animal in this respect, as they are logistically manageable in larger numbers. They 
have consistent anatomic patterns in their coronary circulation, with minimal collateral 
circulation 82. This allowed researchers to achieve a consistent ligation result – enabling 
researchers to produce consistently and sufficiently large infarcted areas, which are 
compatible with survival. The end results are more reliable due to the larger number of 
study subjects. Hence, rats are an established ischaemia-reperfusion injury model 89. 
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Figure 3.1 Species differences in collateral flow and the rate of development of 
infarction. Infarct size, expressed as a percent of area at risk in relation to the 
duration of elapsed ischaemia (followed by reperfusion) in rabbit, pig, dog, rat and 
guinea pig. The rat (not shown) follows the identical profile to the rabbit. 88 
 
There will always be inherent limitations when applying laboratory animal data to 
patients in the clinical setting. Although minimal collateral circulation in rats is an 
advantage in an experimental set-up, it is also a factor that clearly distinguishes it from 
patients; patients with acute coronary syndrome usually develop gradual occlusion of 
the coronary vessels, hence allowing time for collaterals to develop. With this in mind, 
the rat model of in vivo coronary artery ligation may not be the ideal model in studies 
looking at ways of minimising infarct size 90. However, the aims in this study was to 
look at the effects of an initial infarction on MMP2 activation in the heart and its 
subsequent action on the heart during elective global ischaemia as would occur during 
cardiac surgery. Hence, surgical LAD occlusion is a suitable model to achieve these 
aims as long as consistent infarct sizes are achieved in the animals. Initially, studies 
were conducted to determine whether my technique induced reproducible and consistent 
area at risk of the myocardium following surgical ligation, which was at a sufficient size 
that was compatible with the survival of the animal beyond 24 hours of surgery.   
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Subsequently, the final infarct size measurement in the isolated hearts at the end of the 
Langendorff perfusion protocol (when the hearts were not required for tissue samples) 
was carried out. There are various ways to determine infarction in experimental settings. 
This can be done either through histological changes or biochemical changes such as 
dehydrogenase reactions 91, 92. Sufficient ischaemic time is critical for the changes to 
appear. As the infarction protocol is 7 days, the infarction would have been established 
and these changes would have occurred by the time the hearts were assessed for infarct 
size.  
The second part of the experimental design utilised ex-vivo isolated Langendorff heart 
perfusion. The isolated Langendorff heart preparation is an invaluable experimental 
model in studies of cardiovascular function and has contributed greatly to the 
understanding of the heart and its metabolism. It is a cheap and reproducible model and 
being an ex-vivo model, removes the confounding systemic effects 85, 93. It enables 
precise control over perfusate composition and the conditions of perfusion and 
measurements of a variety of indices of tissue function such as contractile function, and 
biochemical markers of metabolic activity or ischaemia or infarction can be carried out. 
Rat hearts are the most stable and best characterised for use in this model.  
Despite its advantages, the isolated heart preparation also has several limitations. Its ex-
vivo state can be a disadvantage, as it removes the systemic interaction with the heart. It 
also suffers from structural and functional deterioration with time, although this can be 
limited with good technique and tissue handling. The type of perfusate may also affect 
the heart. Crystalloid perfusate differs from blood such that, in the absence of 
haemoglobin, the required pO2 of the crystalloid perfusate has to be significantly higher 
than physiological to deliver sufficient oxygen (and this may be damaging), so needs 
significantly higher coronary flow and lastly, with reduced oncotic pressure, it leads to 
rapid tissue oedema. It is generally accepted that a 5-10%/hour reduction in contractile 
function occurs. Hence, it was important to establish the stability of the preparation with 
normal and infarcted hearts over a pre-determined period of time as a test of 
experimental technique. 
Subsequently, preliminary studies were conducted on normal rat hearts to standardise 
the ischaemic duration of hearts required for recovery of LVDP to around 40 to 50%. 
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Establishing this optimal global ischaemic time ensures that there is sufficient capacity 
in the heart to recover and additionally, any intervention of interest under study, such as 
addition of any drugs, if beneficial, will improve the recovery of the function of the 
heart to an extent that it will be detected statistically.   
 
3.2 Methods 
3.2.1 Determination of area at risk of myocardium following LAD ligation 
The anaesthesia and surgery in 11 animals were carried out as previously described in 
Chapter 2, Section 2.1. Following placement of the suture, LAD was ligated as 
described.  The jugular vein was then exposed by an incision and blunt dissection in the 
supraclavicular triangle, with the right side being preferentially used. Between 0.8-1.0 
mls of 3% (w/v) Evans Blue was injected slowly into the jugular vein. The dye would 
enter the non-ischaemic region of the heart, leaving the ischaemic myocardium (risk 
zone) unstained (Fig 3.2), and would be observed in the first few seconds post-injection 
in the heart. After about a minute, the entire animal shows signs of Evans Blue staining. 
Once this happened, the thoracotomy incision was extended to a full clamshell to enable 
the heart to be excised quickly and easily. It was rapidly placed in cold 4% 
formaldehyde and stored at 2-4°C overnight.  
 
Figure 3.2 Heart slices of 2 mm thickness from apex to base (left to right). Pale 
(unstained) tissue indicates the area at risk of infarction. 
The following day, the heart was sliced using a custom-made multi-blade system, which 
cut the heart into 2 mm sections (Fig 3.2). The heart sections were scanned 
immediately, using an Epson Scanner, by placing the sections on the glass scanning 
plate (with a maximum of 2 hearts at a time) and a Western blot glass plate of 0.75 mm 
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thickness placed over the top of the sections (Fig 3.3). PBS was then pipetted under the 
glass plate, at the same time applying slight pressure on the plate to prevent the sections 
moving around. All the sections were surrounded/immersed in the solution. This was to 
ensure high resolution with high fidelity images to enable accurate analysis. 
 
Figure 3.3 Set up of the heart sections for scanning on desktop scanner. (WB – 
western blot). 
 
The heart slices were scanned at 2400 dpi and images saved as uncompressed TIFF 
files. The analysis of area at risk was carried out using SigmaScan software. Volumes of 
the heart were calculated by multiplying the areas by the thickness of the sections (2 
mm).  The volume of the heart at risk was expressed as the percentage of total 
ventricular volume of the heart.  
 
3.2.2 Determination of final infarct size following LAD ligation 
Myocardial infarction was determined using biochemical changes that occurred within 
the myocardium with infarction. Triphenyl tetrazolium chloride (TTC) salts have been 
shown to be a quick and reliable way of assessing infarction 91. Dehydrogenase 
enzymes reduce the salt to a dark red formazan pigment in viable tissues, hence necrotic 
tissue will appear unstained. TTC assessment of viable tissue was found to correlate 
well with histological examination in well-established infarction 92. At the end of the 
isolated Langendorff perfusion protocol, 1% w/v TTC was infused into the heart at 0.5 
ml/gm/min. After about 15 minutes of infusion, the hearts were removed from the 
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cannula and stored at -20°C for 1-2 hours before slicing into 2 mm thickness sections. 
Infarcted myocardium appeared pale yellow and viable myocardium stained brick red 
(Fig 3.4). Planimetry of the infarct area was carried out using Image J software. Once 
again, the volumes of the heart were calculated by multiplying the areas by the 
thickness of the sections (2 mm) and the infarct size expressed as the percentage of the 
total ventricular volume.  
 
 
Figure 3.4 Representative heart sections with TTC staining showing infarcted 
myocardium (pale yellow) and viable myocardium (brick red). 
 
3.2.3 Assessment of stability of isolated Langendorff heart perfusion with 
normal and infarcted hearts 
Normal, adult male Wistar rats (n=3) and adult male Wistar rats that had been subjected 
to surgical LAD ligation (n=5) 7 days prior to ex-vivo perfusion were used. Surgical 
ligation of the LAD was as described in Chapter 2, Section 2.1 and the technique of 
isolated Langendorff perfusion as described in Chapter 2, Section 2.2. The hearts were 
harvested and perfused with Krebs-Henseleit buffer at a constant pressure of 100 
cmH2O at 37oC, continuously gassed with a mixture of 95% oxygen: 5% carbon dioxide 
for 120 min. The HR, LVDP, LVEDP was monitored and acquired continuously, with 
measurement of coronary flow every 10 min (after the initial 20 min of equilibration); 
values are expressed as mean±SEM. For infarcted hearts, the exclusion criteria for 
LVDP was set at a slightly lower value compared to normal hearts. Infarcted hearts that 
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did not achieve LVDP ≥90 mmHg were excluded from the study. The difference in the 
changes in each parameter between normal and infarcted hearts was analysed using 
Student’s t-test. A value of p<0.05 was considered statistically significant. 
 
3.2.4 Determination of optimal normothermic ischaemic time during isolated 
Langendorff perfusion protocol in normal hearts 
Hearts from normal male Wistar rats (n=3-5 in each groups) were used for isolated heart 
perfusion as described in Chapter 2, Section 2.2. The hearts were equilibrated with 
aerobic perfusion for 20 min, before inducing global ischaemia (by clamping the aortic 
inflow line) for 20, 30 or 40 min, followed by aerobic reperfusion for 60 min (Fig 3.5). 
The HR, LVDP and LVEDP were monitored and acquired continuously. The coronary 
flow was measured during baseline aerobic perfusion and every 10 min during the 
reperfusion period.  
 
Figure 3.5 Langendorff heart perfusion protocol to determine optimal ischaemic time 
in normal hearts 
 
Contracture parameters during the ischaemic period were noted. The onset of 
contracture was defined as a rise of  ≥2 mmHg in the LVEDP (Fig 3.6).  
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Figure 3.6 Representative LabChart recording during isolated Langendorff perfusion 
showing continuous acquisition of LVP (LV pressure) over time.  
Blue dotted line indicates the time at which the aortic inflow line was clamped, hence 
inducing global ischaemia. The time taken as the onset of contracture and peak 





3.3.1 Determination of area at risk of myocardium following LAD ligation 
A total of 11 rats were subjected to permanent LAD ligation. In this study, mean area at 
risk of 49.0± 1.7% following the ligation was achieved. The minimum area was 42.4% 
and the maximum area was 61.2% with a median of 47.9%. The data showed that the 
mean and median are very close, with a small range of 95% confidence interval, 
indicating a tight spread of data (Fig 3.7). Hence, LAD ligation in the rats produced a 
consistent and reproducible area at risk of myocardium. 
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Number of values 11 
    
Minimum 42.40 
25% Percentile 45.20 
Median 47.90 
75% Percentile 51.90 
Maximum 61.20 
    
Mean 48.98 
Std. Deviation 5.477 
Std. Error 1.651 
    
Lower 95% CI of 
mean 45.30 
Upper 95% CI of 
mean 52.66 
    
Sum 538.8 
 
Figure 3.7 Graph showing the distribution of the % area at risk following LAD ligation. 
 
 
3.3.2 Determination of final infarct size following LAD ligation 
A total of 53 infarcted hearts, after various isolated Langendorff perfusion protocols, 
were included in this analysis. The mean infarct size (expressed as % of ventricular 
volume) was 20.1±0.9%, with a median of 19.1% (Fig 3.8). The 95% confidence 
interval lies between 18.4 to 21.8%. This again indicated a tight spread of data, 
implying that the final infarct size as a result of LAD ligation in these rats were 
consistent. 
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Number of values 53 
    
Minimum 10.00 
25% Percentile 16.30 
Median 19.10 
75% Percentile 22.90 
Maximum 47.10 
    
Mean 20.10 
Std. Deviation 6.269 
Std. Error 0.8611 
    
Lower 95% CI of 
mean 18.37 
Upper 95% CI of 
mean 21.82 
    
Sum 1065 
 
Figure 3.8 Graph showing tight distribution of final infarct size obtained, confirming 
consistency and reproducibility. 
 
3.3.3 Assessment of stability of isolated Langendorff heart perfusion with 
normal and infarcted hearts 
A total of n=8 infarcted hearts were excluded from the whole study period due to failure 
to achieve a minimum LVDP of ≥90 mmHg. These hearts that failed to meet the criteria 
were mostly encountered within the first 4 weeks of the study period, and was probably 
secondary to my learning curve. The effects of continuous aerobic perfusion in normal 
and infarcted hearts on LVDP, LVEDP, HR and CF are shown in Fig 3.9. In normal 
hearts, after 20 min of equilibration with aerobic perfusion, a mean LVDP of 125±12 
mmHg was achieved. There was a small dip in the mean LVDP after 60 min of aerobic 
perfusion, before gradually stabilising again during the second hour of aerobic 
perfusion, with a further drop towards the end of the perfusion period. After 120 min of 
continuous aerobic perfusion, the mean LVDP decreased to 96±8 mmHg, which is a 
total attrition of 22.7±1% in the LVDP compared to baseline.  In the infarcted hearts, 
after 20 min of equilibration, mean LVDP achieved was 128±8 mmHg. Throughout the 
120 min continuous aerobic perfusion, there was gradual decrease in mean LVDP.  














Figure 3.9 Physiological parameters (i) LVDP, (ii) LVEDP, (iii) HR and (iv) CF in normal 
and infarcted hearts during 120 min of continuous aerobic Langendorff perfusion. 
n=3 normal hearts and n=5 infarcted hearts. 
 
 
At the end of the 120 min perfusion, the mean LVDP in infarcted hearts was 102±3, 
which is a total of 19.5±8% decrease from its baseline value. The % reduction in LVDP 
in normal and infarcted hearts was not significantly (p=0.59) different (Fig 3.10).  





Figure 3.10 % reduction in LVDP in normal and infarcted hearts at the end of 120 min 
of continuous aerobic isolated Langendorff perfusion compared to after 20 min of 
equilibration. n=3 normal hearts, n=5 infarcted hearts. 
 
At the beginning of each perfusion protocol, the volume in the balloon was adjusted to 
achieve LVEDP of between 5 to 10 mmHg. In normal hearts, there was progressive 
decrease in the LVEDP during the first 60 min of aerobic perfusion, and stabilising for 
the remaining perfusion period. At the end of the perfusion protocol, there was a 
53.7±13% decrease compared to its baseline value. In infarcted hearts, the LVEDP 
remained fairly constant throughout the perfusion period, with a 25.4±9% drop at the 
end of perfusion compared to baseline. Again, the change in LVEDP at the end of 
perfusion compared to baseline values was not significantly (p=0.12) different between 
the 2 groups. The HR in normal hearts was quite stable throughout the perfusion period, 
whilst the HR in infarcted hearts had a very gradual deterioration throughout the 
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perfusion period. CF in both groups of hearts again showed gradual deterioration 
throughout the perfusion period.  
 Table 3.1 Physiological parameters i.e HR, LVDP, LVEDP and CF (mean values ± 
SEM) after equilibration with aerobic perfusion for 20 min (baseline) and at the end of 
120 min continuous aerobic isolated Langendorff perfusion period, with the % 
change in the values. 
There was no significant (p>0.05) difference in the % change in each parameter 
between the normal and infarcted hearts at the end of the perfusion period. However, 
the coronary flow was significantly different between the normal and infarcted hearts 
at baseline and after 120 min of continuous perfusion. 
 




HR Baseline 293±21 242±17 (p=0.11) 
(beats/min) End 288±20 204±22 (p=0.04) 
 Change (%) 5.7±2 19.5±8  (p=0.26) 
LVDP Baseline 125±12 128±8 (p=0.80) 
(mmHg) End 96±8 102±3 (p=0.42) 
 Change (%) 22.7±1 19.7±4  (p=0.59) 
LVEDP Baseline 7±2 8±2 (p=0.68) 
(mmHg) End 2±1 6±2 (p=0.18) 
 Change (%) 53.7±13 25.4±9  (p=0.12) 
CF Baseline 7.8±0.2 11.5±0.5 (p=0.002) 
(mls/min) End 6.2±0.3 8.6±0.6 (p=0.03) 
 Change (%) 20.8±5 25.7±3  (p=0.39) 
 
Chapter 3: The experimental design 
83 
3.3.4 Determination of optimal normothermic ischaemic time during isolated 
Langendorff perfusion protocol in normal hearts 
During ischaemia, the time taken for contracture to develop in the hearts subjected to 
different ischaemic times was not significantly (p=0.56) different (13±2 min in 20 min 
ischaemia; 11±2 min in 30 min ischaemia; 14±2 min in 40 min ischaemia) (Fig 3.11). 
The time taken to reach peak contracture was between 16 to 19 min in all 3 groups. The 
peak contracture was slightly higher in hearts subjected to 40 min of ischaemia at 97±11 
mmHg, but again, this was not statistically significant compared to the other 2 groups 







Figure 3.11 Contracture parameters during ischaemia in hearts subjected to 20, 30 
and 40 min of global ischaemia. n=3 in 20’ I, n=5 in 30’ I and n=3 in 40’ I. 
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As expected, increasing durations of ischaemia caused reduced recovery of LVDP; with 
20 min of ischaemia, LVDP recovery was much more rapid, even during the early 
reperfusion period compared to the slow and gradual recovery profile of hearts 
subjected to 30 or 40 min of ischaemia (Fig 3.12i). The final recovery of LVDP (% pre-
ischaemic) at 60 min of reperfusion was 68±13%, 39±5% and 25±6% after 20, 30 or 40 






Figure 3.12 Recovery of LVDP during reperfusion after various ischaemic times. (i) 
Recovery profile during reperfusion (ii) Final recovery of LVDP at 60 min reperfusion. 
n=3 in 20 min, n=5 in 30 min and n=3 in 40 min ischaemia. 
Chapter 3: The experimental design 
85 
With 20 min of ischaemia, LVEDP continually decreases with reperfusion, but after 30 
or 40 min of ischaemia, LVEDP rapidly increases to a peak at 10 min of reperfusion and 
subsequently declined gradually with reperfusion, but remains more elevated with 
increasing ischaemic times (Fig 3.13). 
 
 
Figure 3.13 LVEDP profile during 60 min of reperfusion after various ischaemic times. 
n=3 in 20 min, n=5 in 30 min and n=3 in 40 min ischaemia. 
 
 
The recovery of coronary flow (CF) was also reduced with increasing ischaemic 
durations. The pattern of recovery was similar in all 3 groups, with rapid recovery 
within 10 min of reperfusion, followed by gradual decline throughout reperfusion, with 
a final recovery of 87±4%, 69±9% and 57±3% with increasing ischaemic times 
respectively (Fig 3.14i). HR recovered well in all 3 groups (Fig 3.14ii). 
 









 Figure 3.14 Functional recovery of (i) CF and (ii) HR during reperfusion after various 
ischaemic times. First CF measurement was taken during the first minute of 
reperfusion. n=3 in 20 min, n=5 in 30 min and n=3 in 40 min ischaemia. 
Hence, based on these results, 30 min of global normothermic ischaemia was chosen as 
the optimal duration for subsequent studies.  
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3.4 Discussion 
In this study, we want to use an animal model that mimics an emerging and clinically 
relevant scenario, namely, patients who present with ACS needing urgent or emergent 
CABG surgery. As this is a proof of principle study to determine whether there is a 
relationship between MMP2 and acute ischaemia-reperfusion in the setting of a 
previous myocardial infarction, rodents were chosen as a screening animal. In vivo 
surgical LAD ligation of the animals were used as a means of inducing myocardial 
infarction. Hence, to standardise the experimental design, it is of utmost importance that 
the area at risk of infarction of the myocardium following LAD ligation is consistent 
within animals, even if the ultimate infarct size per se is not the endpoint of 
cardioprotection in our study. Myocardial infarction is induced in this study to provide 
an initial injury stimulus to the myocardium to ‘prime’ or activate MMP2 in the 
myocardium. Thus, it was a critical balance to produce an area that was sufficiently 
large to cause significant myocardial infarction, yet not large enough that it was not 
compatible with survival beyond 7 days. The results obtained in Section 3.3.1 indeed 
showed that the area at risk of infarction was consistent, implying that the surgical 
procedure, suture placement and ligation of each animal were consistent. The end result 
was that the myocardium in each animal was subjected to the same ischaemic stress. 
The exact procedure carried out was also compatible with survival of the animals for 7 
days.  
The presence and consistency of ultimate myocardial infarction was also confirmed 
with assessment of the infarct size. The results in Section 3.3.2 showed that LAD 
ligation carried out resulted in myocardial infarction and this was again consistent. In 
the literature, infarct sizes from ligation of LAD range from 4% to about 50% of LV 
volume 94-99. Hence, the infarct sizes obtained in this study of around 20% of total 
ventricular volume are comparable to other laboratories.  
Nonetheless, we recognised that the model used here is not without its disadvantages. 
The rats used were young adult rats, which may not be equivalent to the 60 year-old 
patients seen in clinical settings. These rats are also healthy rats without any co-
morbidity or on any medical therapy for existing diseases. The underlying pathology of 
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ACS is almost certainly not duplicated exactly in the animals as their coronary arteries 
are essentially normal.  
In the stability studies for isolated Langendorff heart perfusion, all the parameters 
measured, namely the HR, LVDP, LVEDP and CF remained fairly stable with a slight 
decrease with time. The attrition of LVDP was about 10%/hour in both normal and 
infarcted hearts, which is comparable with the general consensus 85, 93. There was no 
significant (p>0.05) difference between normal and infarcted hearts in terms of the 
different parameters measured or in the degree of change at the end of the 120 min 
perfusion protocol compared to after the initial equilibration period. This implied that 
both the normal and infarcted hearts were stable on this preparation and thus will allow 
meaningful use of this model to study the effects of global ischaemia on the mechanical 
function in these 2 groups of hearts. It may have been unexpected that there was no 
significant difference in LVDP achieved after equilibration with aerobic perfusion 
between normal or infarcted hearts. I have deliberately excluded infarcted hearts that 
did not achieve LVDP ≥90 mmHg because it would be difficult to ascertain whether 
LVDP ≤90 mmHg in the infarcted hearts was due to myocardial infarction or technical 
problems with the preparation. Unexpectedly, the coronary flow in infarcted hearts after 
baseline equilibration and at the end of continuous perfusion was significantly higher 
compared to normal hearts. Remodelling of infarcted hearts 7 days after the initial 
infarction, leading to increased coronary flow, may account for this difference. 
Unfortunately, I did not measure the weight of normal or infarcted hearts prior to 
Langendorff perfusion or at the end of the perfusion protocol. 
The function of the heart can be assessed using the relationship between relative 
intraventricular pressure and volume relationship during cardiac cycle 100; however 
pressure-volume relationship in the LV is rather complex. It is not possible to measure 
volume directly in the LV chamber and hence pressure is usually measured (depending 
on the model used; mean developed pressure using an intraventricular balloon or direct 
pressure measurement using a pressure catheter) and used as a surrogate for function. 
Besides, after infarction, there may be geometrical alteration in the LV chamber, with 
thinning of infarcted region and compensatory hypertrophy of uninfarcted region of the 
myocardium. It would have been ideal to be able to carry out haemodynamic studies 
with pressure volume (PV) catheters to acquire PV loops for each heart. This allows 
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accurate characterisation and comparison of haemodynamic function in normal and 
infarcted hearts. However, due to the constraint of time, it was not possible to carry out 
this part of the investigation even though this technology was available.  
Although there was no significant difference between the baseline LVEDP or at the end 
of the perfusion protocol between normal or infarcted hearts, there was a trend towards 
a slightly higher LVEDP in the infarcted hearts at the end of the 120 min perfusion. It is 
important to note that the balloon volume was not adjusted at any time during the 
perfusion period after the optimal values for LVDP and LVEDP were achieved shortly 
after cannulation of the isolated hearts i.e at the beginning of the perfusion. A higher 
volume required to inflate the balloon to achieve adequate LVDP may imply increased 
wall tension in the LV, hence increasing myocardial oxygen consumption. This model 
is a rather over-simplification of an extremely complex relationship with multiple 
assumptions made. After much deliberation and contemplation, we decided to accept 
the findings at face value; that infarcted hearts could indeed achieve a reasonable and 
equivalent LVDP to normal hearts when perfused in an isolated heart perfusion 
preparation, albeit with a slightly higher LVEDP (but not statistically significant). With 
these preliminary studies, it was important to establish and show that, a consistent area 
of myocardium at risk of infarction with surgical LAD ligation was induced and that 
after 7 days, the infarcted hearts were a stable preparation in an ex-vivo isolated 
Langendorff heart perfusion over a 120-min period. It perhaps correlates rather well 
with the experience clinically, with the majority of patients undergoing CABG having a 
good ejection fraction, which is a common clinical index of cardiac function 70, 71. 
Patients with ACS, especially in the NSTEMI subgroup, often have good LV, with good 
ejection fraction, as measured by transthoracic echocardiography. In an unstressed state, 
an infarcted heart could compensate perfectly well to achieve an adequate cardiac 
output. However, when stressed further by global ischaemia, such as that imposed by 
elective cardiac surgery, the heart may not recover as well as a heart not recently 
stressed by myocardial infarction.   
The aim in the final part of this section was to establish the optimal global 
normothermic ischaemic time in normal hearts. If the ischaemic time is too short, the 
hearts will recover to a high level and it will be difficult to detect any statistically 
significant improvement due to pharmacological intervention. On the other hand, if the 
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ischaemic time is too long, there may be irreversible cellular damage leading to poor 
recovery, which is not amenable to supposedly beneficial intervention improving 
recovery. As expected, there was progressive decline in the final recovery of LVDP 
with increasing duration of global ischaemia. From previous experience in the 
laboratory, the ischaemic time that results in approximately 40% recovery of LVDP 
compared to the pre-ischaemic function is usually ideal.  
In summary, we have shown that with surgical ligation of the LAD artery, consistent 
area at risk of infarction and final myocardial infarction were produced in the rats, 
allowing us to produce rats that resemble patients in actual clinical setting with 
myocardial infarction. I have also demonstrated that both normal and infarcted hearts 
were stable under my experimental conditions and techniques over a period of 120 min 
of continuous aerobic perfusion using the isolated Langendorff heart perfusion 
preparation. In addition, an ischaemic time of 30 min of global no-flow ischaemia was 
shown to be the optimal ischaemic duration to examine further interventions aimed at 
determining the role of additional global ischaemia in previously infarcted hearts. This 
will be described in the following chapters.  
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4 PHYSIOLOGICAL EFFECTS OF ADDITIONAL 
ISCHAEMIA-REPERFUSION ON INFARCTED 
HEARTS 
4.1 Introduction 
As mentioned in Chapter 1, there are various studies such as the National Adult Cardiac 
Surgical Database Report by the Society for Cardiothoracic Surgery of Great Britain 
and Ireland 70 and the review using California Discharge Data 71 showing that patients 
with ACS requiring urgent or emergency CABG have an associated higher mortality 
and morbidity. Recently, diagnostic sensitivity and specificity has improved to the 
extent that patients can be further classified into different categories within the spectrum 
of ACS. Emergency CABG (within 48 hours of STEMI) in patients with STEMI carries 
a much higher mortality, up to 20% in the series published by Hagl et al 66. In the joint 
guidelines published by ESC/EACTS, emergency CABG in patients presenting with 
STEMI is only advocated when primary PCI has failed or is not possible, or when a 
significant proportion of the myocardium is at risk and surgical revascularisation could 
be completed before further necrosis occurs 65, 67. As for urgent CABG, there was a 
strong inverse relationship between the outcome of surgery and the time that elapsed 
since STEMI 64, 101. In other words, CABG should only be considered as the last resort, 
or only an option if there were other indications, such as mechanical complication in 
terms of acute rupture of the chordae tendinae or ventricular septum.  
The optimal treatment strategy in patients with NSTEMI is not as well-defined as 
STEMI patients (American Heart Association (AHA)/ESC guidelines) 67, 102. One of the 
reasons is that patients presenting with NSTEMI are a very heterogenous group. Current 
efforts are directed at risk stratification of this cohort of patients to develop a tool to 
direct management according to risk factors. Risk scores are used to identify the optimal 
timing of invasive diagnostic tests in the first instance. The other major issue to be 
resolved is the type of revascularisation, including the role of surgery in the 
management strategy. There are currently no available randomised controlled trials 
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(RCTs) to compare different revascularisation strategies in this group of patients. 
Propensity studies may shed some light but are unlikely to provide the ultimate answer.  
The timing of surgery from diagnosis of MI has not been resolved currently. Some 
studies suggested that the risk of surgery for patients with acute MI was not greater 
compared to elective CABG 103, 104. However, the timing of surgery may vary from 7 to 
30 days following MI. DeWood and co-workers reported significant improvement in 
global and regional wall motion of the LV if surgery was performed very early within 6 
hours of MI, with a reasonable mortality rate of 2.1% 105. But, a more recent study by 
Voisine et al contradicted this finding 106; in their cohort of patients, peri-operative 
mortality in patients having CABG within 6 hours of experiencing MI was 19.2%. 
Interestingly, the increased mortality was not seen in patients under the age of 65 when 
CABG was performed within 6 hours of MI. However, if the window of 6 hours was 
missed, the risk of surgery was shown to increase within 48 hours and up to 3 or 7 days 
of MI 71, 101. Weiss and co-workers 71 raised the possibility of biological factors such as 
enhanced systemic inflammatory response being the culprit for the increased risk, as 
was certainly implicated in a study by Dixon with upregulation of MT1-MMP activity 
42. Alternatively, human or logistical issues (such as an emergency situation with less 
staff and less controlled environment), may be a contributing factor. Our studies aim to 
use an animal model simulating the clinical scenario to study the contribution of 
biological factors such as priming of bioactive molecules from an initial ischaemic 
insult on the myocardium. Additionally, the effect of timing (3 days vs 7 days post MI) 
for an elective global ischaemia-reperfusion injury (as would occur during cardiac 
surgery) imposed on the infarcted myocardium, in terms of the recovery of the 
myocardium, was also studied using an isolated rat heart perfusion model.  
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4.2 Methods 
4.2.1 Effect of additional global ischaemia-reperfusion on infarcted hearts  
The protocols for these studies are shown in Fig 4.1. Four groups (n=5-6 hearts/group) 
of isolated hearts were perfused using the Langendorff perfusion model as previously 
described in Chapter 2, Section 2.2. Group (i) was the control group where normal (i.e 
non-infarcted), adult male hearts were used. Group (ii) consisted of adult male hearts 
where the LAD was surgically ligated as described in Chapter 2, Section 2.1, to induce 
myocardial infarction, with the rats allowed to recover for 7 days prior to harvesting the 
hearts for ex-vivo perfusion. Group (iii) was adult male hearts subjected to LAD 
ligation as described, with the rats allowed to recover for 3 days prior to harvesting the 
hearts for ex-vivo perfusion. Group (iv) was adult male rats subjected to sham 
thoracotomy; the rats were anaesthetised and underwent anterior thoracotomy up to 
exteriorisation of the hearts (the pericardium was opened and the heart was also 
exteriorised temporarily) as Group (ii), but suture ligation was not applied to the LAD. 
The rats were also allowed to recover for 7 days prior to the experiments.  
Isolated Langendorff heart perfusion was carried out as described in Chapter 2, Section 
2.2. The hearts were equilibrated with aerobic perfusion for 20 min when baseline 
function parameters were measured, before global ischaemia was induced by clamping 
the aortic inflow line for 30 min (as defined in studies described in Chapter 3, Section 
3.3.4). Global ischaemia was maintained at 37°C. After this period, the hearts were 
reperfused for a further 60 min with aerobic perfusion (Fig 4.1). 
 
Figure 4.1 Langendorff perfusion protocol for isolated heart perfusion. 
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The HR, LVSP and LVEDP were monitored and acquired continuously and coronary 
flow was measured every 10 minutes during the reperfusion period. LVDP was derived 
from LVSP-LVEDP. The recovery profiles of the groups were compared using the 
exponential association analysis, which is a nonlinear regression analysis by 
constructing a best-fit curve and comparing the constants of the best-fit curve between 
the groups. The final recovery was compared using ANOVA, with post-hoc Dunnett’s 
test for multiple comparisons. A value of p<0.05 was considered statistically significant.  
 
4.3 Results 
4.3.1 Contracture parameters during ischaemia 
Contracture parameters such as the time taken from ischaemia to develop contracture, 
the time taken to develop peak contracture and the peak contracture developed were 
considered. The time taken for hearts in each group to develop contracture (from 
cessation of aerobic perfusion) were 11±2 minutes, 14±0 minutes, 12±1 minutes and 
14±0 minutes in normal, 7-day infarct, 3-day infarct and sham hearts respectively (Fig 
4.2i). These were not significantly (p=0.1) different. The times taken to reach peak 
contracture were also not significantly (p=0.3) different between the groups, ranging 
between 16 to 18 min (Fig 4.2ii). The peak contracture developed in the hearts were 
86±11 mmHg in normal, 50±8 mmHg in 7-day infarct, 53±4 mmHg in 3-day infarct, 
and 71±6 mmHg in sham hearts respectively (Fig 4.2iii). The peak in normal hearts was 















Figure 4.2 Contracture parameters (i) time to contracture, (ii) time to peak contracture 
and (iii) peak contracture developed during ischaemia; n=5 normal, n=6 infarct 7d, 
n=6 infarct 3d and n=6 sham. * p=0.006 
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4.3.2 Recovery during reperfusion 
The recovery profiles of LVDP (% pre-ischaemic) of normal, 3-day infarct and sham 
hearts during the 60 min reperfusion period were very similar. There was slow and 
gradual recovery throughout the 60 min reperfusion period, reaching a plateau around 
50 min of reperfusion (Fig 4.3i). On the other hand, LVDP recovery in the 7-day infarct 
group was significantly (p<0.0001) worse, reaching a lower plateau at 40 min 
reperfusion. The final LVDP recovery in the 7-day infarct hearts was only 22±2%, 
which was significantly (p<0.02) lower compared to the other groups (39±5% in 
normal, 32±5% in 3-day infarct and 39±3% in sham hearts) (Fig 4.3ii). 
LVEDP in all groups at the end of global ischaemia was higher than baseline, reaching 
a peak within 10 min of reperfusion, before gradually decreasing throughout 
reperfusion, although it remained more elevated compared to baseline (Fig 4.4). The 
LVEDP at the end of reperfusion ranged between 56 – 73 mmHg and was not 















Figure 4.3 Recovery of LVDP (% pre-ischaemic values) in each group during 
reperfusion after global ischaemia. n=5 normal, n=6 infarct 7d, n=6 infarct 3d, n=6 
sham. 
(i) LVDP recovery profiles * p<0.0001 (ii) Final LVDP recovery in each group. Ψ p<0.02 





Figure 4.4 Recovery of LVEDP during reperfusion after global ischaemia. n=5 normal, 
n=6 infarct 7d, n=6 infarct 3d and n=6 sham. 
 
The recovery profiles for HR and CF during the 60 min reperfusion phase are shown in 
Fig 4.5. The recovery of HR in all groups was very similar. There was rapid recovery to 
close to baseline (pre-ischaemic) values within 10 minutes of reperfusion. The final 
recovery (% pre-ischaemic) of HR for normal, 7-day infarct, 3-day infarct and sham 
hearts were 87±5%, 83±4%, 88±4% and 83±7% respectively. Similar rapid recovery 
was seen with CF, although it did not recover quite as well as HR. The final recovery of 
CF showed that the infarcted group tended to have a lower recovery (normal 69±9%, 7-
day infarct 56±3%, 3-day infarct 47±1% and sham 65±7%). The final recovery of CF in 
3-day infarct hearts was significantly (p=0.05) lower compared to normal hearts. 







Figure 4.5 Recovery of (i) HR and (ii) CF during reperfusion after global ischaemia. 
First CF measurement taken during the first minute of reperfusion. n=5 normal, n=6 
infarct 7d, n=6 infarct 3d and n=6 sham. 
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4.4 Discussion 
The optimal timing from MI to CABG surgery has been an ongoing debate, much more 
so in the recent years due to changes in the management of patients with ACS. There 
are advocates for early surgery, citing results from institutional reports with low peri-
operative mortality. As previously mentioned, De Wood and colleagues advocated early 
surgery within 6 hours of MI because mortality in their patients was low and early 
surgical revascularisation was associated with significant improvement in regional and 
global wall motion in the LV 105. Braxton and co-workers suggested that 48 hours was 
an acceptable duration to perform CABG after MI 107. In their study, in the subgroup of 
patients with STEMI, surgical mortality was 50% when CABG was performed within 
48 hours of STEMI compared to a mortality of 7.7% when surgery was performed more 
than 48 hours after STEMI. At the same time, there are also advocates for delayed 
surgery. Weiss and co-workers showed the temporal trend in mortality with time from 
MI to surgery, with maximal mortality within the first 24 hours 71; Lee and co-workers 
showed that high mortality was seen in patients undergoing CABG within 3 days of MI 
101; Voisine and associates showed that in patients undergoing CABG within the first 24 
hours of MI, mortality was around 10% or higher 106. However, it is rather difficult to 
compare these reported series. All studies were retrospective studies. The patients in De 
Wood’s series were considerable younger, with a mean age of 53 years, compared to the 
other studies, with a mean age of around 60 years. The study period varied between 
studies; some were carried out in the early 1990s, some in the early 2000s and some 
ranged from 1990s to 2000s. The pathology also differed between series; some only 
considered STEMI, whilst others were all-inclusive. If indeed duration between MI and 
CABG surgery is a predictor of higher mortality, the cause may be multi-factorial such 
as presence of co-morbidity in patients, underlying pathology with its associated 
biological response such as systemic inflammatory response and haemodynamic status. 
Hence, with our animal model, we attempted to remove all the other variables that 
might cause cardiac dysfunction in this setting and focus on purely the biological 
response and effect in the myocardium when subjected to regional infarction initially, 
before subsequent global ischaemia-reperfusion. As mentioned in Chapter 1, Section 
1.3.3, Dixon and co-workers have previously shown there was up-regulation of MT1-
MMP in the heart subjected to surgical ligation of coronary artery, even 3 weeks after 
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the infarction 42, which correlated with decreased regional stroke work. To our 
knowledge, our study is the first animal model study of the effects of global ischaemia-
reperfusion on previously infarcted hearts, with particular attention to the influence of 
timing between the ischaemic injuries. The MI model in rats used here allowed a proper 
and simplified way of investigating purely the contribution of biological factors in 
causing heart dysfunction in the infarcted myocardium when it is further stressed by 
another ischaemic burden. The main aim of these studies was to assess the impact of 2 
consecutive ischaemic burdens, as well as the interval between the insults on the 
capacity of the heart to recover its mechanical function. Given the evidence available so 
far in the literature, it will be prudent to study an early and late timing before imposing 
a second global ischaemia. Due to logistical constraint during the initial period of these 
studies, 7 days was the shortest time possible between induction of surgical MI and ex-
vivo heart perfusion. This was due to the fact that surgery had to be perfomed in a 
different biological services unit (BSU) on a separate campus (due to refurbishment of 
BSU in the department), with only a weekly transport of animals between the BSUs. 
The 3-day infarct protocol was only carried out towards the end of the study period once 
the construction work was completed. For these studies, it was decided that sham 
operation was not necessary as our previous studies at 7-days had demonstrated that 
hearts from the sham group were almost identical to normal hearts.  
In all groups, the development of contracture started after a similar period of global 
ischaemia, reaching peak contracture shortly after that. It is surprising that the infarct 
groups, both early and late, seemed to have a lower peak contracture compared to either 
normal or sham hearts. With reperfusion, there was an early and brief period of 
hypercontracture in all hearts, consistent with the generation of reactive oxygen species 
(ROS), resynthesis of adenosine triphosphate (ATP) in the presence of elevated calcium 
concentration and induction of mitochondrial permeability transition pore108. However, 
with sustained reperfusion, the diastolic pressure of all groups seemed to improve 
somewhat and be comparable again. It was once thought that contracture indices in 
isolated heart models implied severity of ischaemic and irreversible myocardial injury, 
but recent studies disputed this 109. Preconditioning and cardioplegia affects contracture 
in different ways, yet recovery of myocardial contractility remained similar. Contracture 
reflects the changes in the metabolic state and activity in the myocytes. When ATP 
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levels are depleted to around 12 µmoles/g dry weight, it seemed to trigger development 
of contracture in the myocardium 110, with the suggestion that availability of calcium 
affected the peak of contracture. Different metabolic activity in normal and ischaemic 
myocardium may explain the differences in peak contracture developed that we 
observed in the normal and infarcted hearts. It would, therefore, be interesting to study 
the tissue metabolites in these groups to determine if there was any difference in high-
energy phosphates. Our study was also only a short-term study and it would be 
interesting to see whether there is any long-term consequence in remodelling of the 
ventricles.  
The recovery of LVDP we found in the study demonstrated that infarcted myocardium 
has less capacity for recovery of global function following another global ischaemia-
reperfusion injury, but, unexpectedly only in the 7-day infarct hearts. The rate of 
recovery in the 7-day infarct group was slower compared to normal, 3-day infarct or 
sham hearts with a lower maximal recovery of the LVDP. In our study, we used LVDP 
as an index of global LV function.  This suggests that the duration between the 
ischaemic insults has an impact on recovery of mechanical function of the heart. The 3-
day infarct hearts may have been protected by the second window of protection of 
ischaemic pre-conditioning 111. Various signalling pathways have been shown to be 
activated by ischaemia-reperfusion injury 75, 112. Other than signalling pathways, there 
could also be activation of various bioactive molecules (such as MMP2) and molecular 
events that are time-dependent. It could also imply that function of bioactive molecules 
or its activation depends on the duration after the insult. As described in Chapter 1, 
optimal timing of MMP inhibition may be beneficial in remodelling of the LV, but 
prolonged inhibition may have the opposite of the desired effects. Besides LVDP, the 
recovery of CF was the other parameter that was different between the groups; however, 
this time, it was significantly lower in the 3-day infarct hearts compared to normal 
hearts. This could imply that there was more endothelial dysfunction with increased 
vascular tone in the early period after infarction. The balance between vasoconstriction 
and vasodilation in the endothelium may have changed between 3 and 7 days of 
infarction. Again, this could be explained by differential activation or the temporal 
effects of MMP2 as it can both vasoconstrict and vasodilate.  
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In summary, studies described in this chapter demonstrated clearly that first of all, the 
infarcted myocardium had less capacity to recover its contractile function when 
subjected to a further period of global ischaemia. The timing of the second insult also 
had an impact on the ability of the myocardium to recover. There must be biological 
factors at play in the myocardium to explain the results we found. Perhaps MMP2 has a 
role in causing the dysfunction seen in the 7-day infarct hearts. What is the activity of 
MMP2 in the infarcted myocardium during reperfusion after the subsequent global 
ischaemia? Could it be that MMP2 may be beneficial to the infarcted hearts during the 
early days of infarction? As explained earlier, we would have liked to move on to assess 
myocardial MMP2 activity in both the 3-day infarct hearts and 7-day infarct hearts to 
ascertain whether a temporal difference in myocardial MMP2 activity may be a possible 
explanation to the phenomenon we see, but unfortunately, due to circumstances beyond 
our control (with the upgrading on BSU within the department), it was not possible to 
do that. In subsequent chapters, we proceeded to study myocardial MMP2 activity in 7-
day infarct hearts initially in an attempt to answer some of these questions. 
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5 MYOCARDIAL MMP2 ACTIVITY DURING AN 
ACUTE ISCHAEMIA-REPERFUSION PHASE 
5.1 Introduction 
In Chapter 4, we demonstrated that infarcted myocardium had less capacity to recover 
contractile function when subjected to further global ischaemia-reperfusion in 
comparison to normal hearts subjected to the same global ischaemia-reperfusion. The 
inability to recover contractile function is a manifestation of intracellular and molecular 
events occurring within the myocytes with ischaemia-reperfusion. With ischaemia, 
anaerobic metabolism will rapidly take over (resulting in intracellular acidosis and loss 
of contractility), with gradual depletion of ATP and ultimately causing irreversible cell 
and microvascular injury 8. The mechanism of myocyte death is due to a combination of 
necrosis, apoptosis and autophagy 72, secondary to the role of calcium (Ca2+) overload 
and generation of ROS both during the ischaemia and reperfusion phase of the injury. 
During ischaemia, intracellular acidosis results in an increase in intracellular sodium 
(Na+), in exchange for the extrusion of excessive protons (H+) generated during 
ischaemia 72. This, in turn, causes a reversal of the sodium-calcium exchanger (NCX) 
leading to a rise in intracellular Ca2+. With reperfusion, intracellular Ca2+ can return to 
normal gradually, oscillate or remained persistently high, depending on the myocyte 
ATP level, intracellular Na+ concentration and ryanodine channel release in the 
sarcoplasmic reticulum. Persistently raised Ca2+ concentration is the culprit in causing 
irreversible cell injury. The other major culprit of cell death is ROS. ROS is generated 
mainly during reperfusion with the introduction of oxygen 72.  ROS can directly or 
indirectly result in myocardial damage and cell death 108. ROS interacts directly with 
lipids and proteins, resulting in alteration of ion channels, leading to Na+ and Ca2+ 
overload and ultimately cell death. Indirectly, ROS may activate signaling pathways, 
such as mitogen-activated protein kinases (MAPK).  
As described in Chapter 1, Section 1.3.3, MMP2 has been implicated in acute 
ischaemia-reperfusion injury of the heart. MMP2 could be linked to ischaemia-
reperfusion in various ways. Signalling pathways activated by ROS, such as MAPK, 
could in turn activate MMP2 and MMP9 113. In an animal model of repetitive ischaemia 
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(RI), it was shown that p38 MAPK was maximally activated on day 3 of the RI protocol 
114 and MMP2 and MMP9 were also activated by the RI protocol, specifically on day 3 
as well 113. When the animals were treated with p38 MAPK inhibitor for 2 days during 
the RI protocol, there was significant reduction in the expression and activation of 
MMP2 and MMP9 113. Other than signalling pathways, ROS may also directly activate 
MMPs. Peroxynitrite, ONOO-, one of the species of ROS, has been shown to directly 
activate MMP2 in myocytes, resulting in myocardial injury 79.  
Once activated, MMP2 could affect processes and structures within the myocytes, thus 
contributing to myocardial injury. For example, in cancer cell culture studies, 
downregulation of MMP2 was consistently shown to induce apoptosis 115, 116. Extensive 
research into acute ischaemia-reperfusion injury has shown that mitochondria are very 
important regulators of cell energetics and viability 72. Experimental evidence suggests 
that MMP2 affects the architecture and function of mitochondria. Transgenic mice over-
expressing MMP2 were shown to have disruption to their mitochondrial structure 117 
and MMP2 inhibition studies in bovine retinal endothelial cells showed that MMP2 
inhibition was associated with decreased mitochondria superoxide production and 
membrane permeability 118. When transgenic mice overexpressing MMP2 were 
subjected to acute ischaemia-reperfusion, the recovery of myocardial function was 
worse compared to wild-type, with evidence of disturbed mitochondrial respiration and 
mitochondrial deformation associated with mitochondrial swelling and loss of integrity 
of membrane and cristae 119. Zhou and co-workers also demonstrated that in a baseline, 
unstressed state, there was no difference in the haemodynamic parameters between the 
transgenic mice over-expressing MMP2 and wild type. However, when subjected to 
acute ischaemia-reperfusion, transgenic mice were more vulnerable and susceptible to 
injury, with less recovery capacity. These studies suggest that MMP2 may have an acute 
role in myocardial ischaemia-reperfusion injury. 
We, therefore, wanted to investigate the role of MMP2 in the increased vulnerability 
seen in the 7-day infarct hearts carried out in studies described in Chapter 4. In order to 
establish any link between MMP2 activity and the cardiac dysfunction observed, we 
determined the temporal effect of ischaemia-reperfusion on MMP2 activity during 
isolated heart perfusion, using different MMP2 activity assays.  
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5.2 Methods 
5.2.1 MMP2 activity (assessed using MMP2 activity assay) in myocardium 
(tissues) during acute ischaemia-reperfusion 
MMP2 activity was measured in isolated hearts from normal, infarcted or sham rats. 
Rats were subjected to LAD ligation as described in Chapter 2, Section 2.1 and the 
sham hearts were subjected to the same surgery (up to and including the stage where the 
heart was exteriorised) as the LAD ligation hearts except that suture ligation of LAD 
was not carried out. All the animals that underwent surgery were recovered for 7 days, 
with free access to food and water. After 7 days, 3 groups of hearts (normal, infarcted 
and sham) were perfused using the isolated Langendorff heart perfusion as described in 
Chapter 2, Section 2.2, with the perfusion protocol as described in Chapter 4, Section 
4.2.1, depicted in Figure 4.1. The hearts were freeze-clamped with liquid nitrogen at 
different time points during the perfusion protocol to collect myocardial tissues for 
analysis (n=3 in each group at each time point). The chosen times were: (i) after 20 min 
of aerobic equilibration (baseline), (ii) at the end of 30 min of normothermic global 
ischaemia (0 min), (iii) 2 min of aerobic reperfusion after 30 min of normothermic 
global ischaemia (2 min), (iv) 5 min of aerobic reperfusion after 30 min of 
normothermic global ischaemia (5 min), (v) after 10 min of aerobic reperfusion after 30 
min of normothermic global ischaemia (10 min). 
The tissues collected were stored at -80°C until use. The hearts were homogenised as 
described in Chapter 2, Section 2.3. The supernatant was collected and used to assess 
MMP2 activity using the MMP2 activity assay (GE Healthcare, Amersham, UK). The 
assay was carried out as described in Chapter 2, Section 2.7. The results of the assay 
were expressed as ng/ml/gm of protein. Statistical analysis was carried out with 
ANOVA test between the groups at different time points, using post-hoc Tukey’s test 
for multiple comparison. A value of p<0.05 was considered statistically significant.  
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5.2.2 MMP2 release (assessed using substrate zymography) in the coronary 
effluent at reperfusion after global ischaemia 
Normal hearts and infarcted hearts were used in this study. Infarcted hearts were 
harvested from rats subjected to LAD ligation as described in Chapter 2, Section 2.1, 
and allowed to recover for 7 days prior to isolated heart perfusion. The 2 groups of 
hearts were perfused in the isolated Langendorff heart perfusion as described in Chapter 
2, Section 2.2, with the perfusion protocol as described in Chapter 4, Section 4.2.1, 
depicted in Figure 4.1. Coronary effluent was collected (6 mls) in each group after 20 
minutes of aerobic equilibration and immediately at reperfusion following 30 minutes of 
normothermic global ischaemia (n=6 in each groups). Cheung and co-workers had 
demonstrated that the release of MMP2 peaked within the first 2 min of reperfusion 
after global ischaemia 35, and the volume of effluent collected for their analysis was 6 
mls. Hence, I decided to collect 6 mls of effluent for analysis. The time taken to collect 
6 mls of effluent at aerobic perfusion averaged at 40 s and  immediately after ischaemia 
was 90 s.  
The effluent was concentrated using Amicon Ultra-15 Centrifugal Filter Unit with 
Ultracel-30 membrane (MerckMillipore, UK), centrifuged at 4000g in 4°C for 10 
minutes. The final volume of the concentrate was between 200-250µl (measured using 
graduation in the filter unit). The concentrate was analysed for protein content using the 
Bradford protein assay as described in Chapter 2, Section 2.4 and used to assess 
gelatinolytic activity using substrate zymography. The presence of MMP2 in the 
effluent was also confirmed using protein (Western) immunoblot as zymography is not 
a specific technique for MMP2. Western blotting was carried out as described in 
Chapter 2, Section 2.5. Quantitative analysis was not performed with Western blotting, 
since the aim was to confirm the presence of MMP2 by detection of the relevant 
molecular bands at both 72 and 62 kDA.  
The sample collection and analysis with zymography was carried out on the same day to 
protect the integrity of the proteins, by preventing freeze-thaw cycle. Coronary effluent 
concentrate, 30 µl, was used in gelatin zymography. Zymography was carried out as 
described in Chapter 2, Section 2.6, with the reagents and incubation times as detailed. 
Gelatinolytic activities were detected as clear bands corresponding to molecular weights 
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of the enzymes. The destained gels were scanned using GenSnap software and band 
density measured using Image J software. Statistical analysis between 2 groups was 




5.3.1 MMP2 activity (assessed using MMP2 activity assay) in myocardium 
(tissues) during acute ischaemia-reperfusion 
The activity of MMP2 in infarcted heart tissues was higher at all the time points 
assessed compared to normal or sham hearts (Fig 5.1).  After aerobic perfusion 
(baseline stability period), MMP2 activity in infarcted heart tissues was significantly 
(p=0.04) higher (at 0.87±0.08 ng/ml/gm of tissue) compared to 0.63±0.02 and 
0.61±0.06 ng/ml/gm in normal and sham groups, respectively. MMP2 activity peaked at 
5 minutes of reperfusion in the infarcted myocardium (1.03 ng/ml/gm of protein), which 
was significantly (p=0.02) higher than that in the normal myocardium (0.576 ng/ml/gm 
of protein). 
 




Figure 5.1 MMP2 activity in normal, infarcted and sham hearts. n=3 in each group at 
each time point. 
MMP2 activity in normal, infarcted and sham hearts at the end of baseline, aerobic 
perfusion and immediately after global ischaemia (0), and at 2, 5, and 10 min of 
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5.3.2 MMP2 release (assessed using substrate zymography) in the coronary 
effluent at reperfusion after global ischaemia 
 
The presence of MMP2 in the effluent of normal and infarcted hearts at the end of 
aerobic perfusion and immediately at reperfusion was confirmed by the detection of  
bands at 72 and 62 kDA (the molecular weights for pro-MMP2 and MMP2, 
respectively) using protein immunoblot. In the coronary effluent, MMP2 activity was 
detected at 72 and 62 kDa, by comparison with MMP2 standard (Calbiochem, 
Nottingham, UK). In normal hearts, 30 min of global ischaemia increased MMP2 
activity in the initial 6 mls of reperfusion effluent to a significantly higher value 
(0.63±0.06 arbitrary unit (AU) vs 0.28±0.08 AU, p=0.02) than that of baseline 
perfusion. MMP2 activity in the coronary effluent of infarcted hearts was higher at both 
72 (p=0.003) and 62 (p=0.0005) kDA compared to the coronary effluent of normal 
hearts at baseline aerobic perfusion (Fig 5.2). However, after 30 min of global 
ischaemia, there was no further increase in MMP2 activity in the effluent of infarcted 
hearts. The release of MMP2 into the initial 6 mls of effluent of both normal and 


































Figure 5.2 MMP2 activity in coronary effluent of normal and infarcted hearts during 
aerobic perfusion and after 30 min of global ischaemia. n=6 in each group. 
(i) Representative Western blots confirming the presence of MMP2 in the coronary 
effluent of infarcted and normal hearts at baseline aerobic perfusion and after 30 min 
of global ischaemia. (ii) Representative zymogram of coronary effluent compared to 
commercially available MMP2 standard. Gelatinolytic bands detected at 72 kDA in all 
samples, with fainter bands at 62 kDA (iii) Densitometric analysis of gelatinolytic 
activities in coronary effluent. NA – effluent in normal hearts at baseline aerobic 
perfusion; NB – effluent in normal hearts after global ischaemia; IA – effluent in 
infarcted hearts at baseline aerobic perfusion; IB – effluent in infarcted hearts after 
global ischaemia. * p<0.05 vs NA, ψ p<0.05 vs NA 
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5.4 Discussion  
It would be ideal to be able to analyse heart tissue homogenates for MMP2 activity in 
its unaltered endogenous state, and its molecular interactions intact. However, this was 
difficult to achieve as the extraction processes, together with various reagents used in 
the process, will interact and may alter the physiological state of MMP2. Although DTT 
should be excluded from the extraction buffers due to its property as a reducing agent, 
the results obtained in Chapter 2, Section 2.3 clearly showed that without DTT, the 
yield of protein extraction was so poor that it may not be possible to perform any assay 
of MMP2 activity at all. The final concentration of DTT added to the buffers was only a 
fifth of the usual concentration used to extract proteins from tissues for immunoblotting 
purposes. This was thought to be a reasonable compromise. Samples from different 
groups were processed under identical conditions and, although this may not truly 
reflect physiological state, it will still allow valid comparisons of MMP2 activity in 
different groups of hearts to establish a proof of principle.  
The most widely used and conventional method to assess MMP2 activity is substrate 
zymography. This is an electrophoretic technique based on SDS-PAGE, where the 
substrate is co-polymerised with the polyacrylamide gel; hence, detection of MMP 
activity is based on molecular weight separation. It is relatively cheap, sensitive, widely 
used (hence allowing comparison with other studies) and is a good screening tool. As 
gelatinolytic activities are detected based on molecular weight (and not from specific 
MMP2 antibody), it may not be entirely accurate, especially in the light of recent 
mounting evidence that MMPs can also be activated by mechanisms other than 
proteolysis, such as s-nitrosylation and phosphorylation 20, 27, 28. Because of these 
limitations in zymography, a new colorimetric assay was also used in this study to 
measure MMP activity. This is a recently developed method, and uses modified pro-
urokinase; it acts as a pro-form of the detection enzyme, which is activated by active 
MMP2 120 121. It is described by the manufacturers (GE Healthcare) to be a precise, 
accurate and quantitative technique, that is also specific for MMP2. However, it is 
considerably more expensive than substrate zymography and has a limited shelf-life 
once the kit is opened; for this reason, studies described in Chapter 2, Section 2.7 were 
performed in an attempt to validate this assay. Despite strict adherence to 
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manufacturer’s instructions, the data show that there was considerable variance in the 
standard curve. Therefore, caution should be exercised in interpreting the absolute 
quantitative values obtained with the assay, especially when the assays were carried out 
on different plates and/or on different days. However, a comparison of trend between 
different groups (if all the samples were analysed on the same plate, with the assay 
carried out at the same time) could still be examined. Despite these disadvantages, the 
assay was still used as it seems to be a more accurate assay of MMP2 activity compared 
to substrate zymography, and it is readily performed in the laboratory. It measures 
active MMP2 based on its activity (and not just presumed active based on it molecular 
weights). The assay consists of 96-well plate, which allows simultaneous comparison of 
the different myocardial samples and hence allowing us to assess if there were any 
differences in the trend of activity between the different groups.  
It is important to establish the temporal relationship between MMP2 and the 
pathophysiology in question. In tumorigenesis, the link between MMPs and the type 
and stage of cancer is important. In a murine model of kidney glomerular disease, 
MMP2 and MMP9 were shown to be detrimental in the early stage of the disease but 
protective in the advanced stage 122. In cardiovascular diseases, high MMP3 activity 
prevented plaque formation but once the plaque is formed, high activity contributes to 
plaque instability, leading to rupture 123. In studies of heart failure using LAD ligation 
models in rats, it was found that the protein level and expression of MMP2 were both 
significantly higher than pre-infarction as early as day 1 post-ligation 33, and remained 
elevated for about 2-3 weeks post MI. After this, both mRNA and protein level 
gradually decreased towards baseline. However, there was a second surge in protein 
level of MMP2 at 10 weeks. Our results concurred with this study, showing that MMP2 
activity in the myocardium was also higher in previously infarcted hearts 7 days after 
LAD ligation compared to normal or sham-operated animals when measured during 
baseline aerobic isolated Langendorff perfusion. Another ischaemic insult was 
superimposed on the infarcted hearts during the period where both activity and 
expression of MMP2 was high, but there was no further surge in MMP2 activity as 
demonstrated by a relatively constant level of activity in the infarcted hearts during the 
acute reperfusion phase. This could suggest that there was maximal activation of MMP2 
after the initial infarction, which was sufficient to reduce the capacity of the infarcted 
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myocardium to tolerate further ischaemic insult. Release of MMP2 into the coronary 
effluent supported this conclusion. For normal hearts, there was an increased MMP2 
release into the effluent after 30 min of global ischaemia, concurring with the results 
reported by Cheung and associates 35. In their study of acute ischaemia-reperfusion in 
isolated Langendorff rat heart perfusion, they found a significant increase in MMP2 in 
the coronary effluent in a time-dependent manner during reperfusion after 20 min of 
global no-flow ischaemia, with a peak of MMP2 in the effluent collected at 1 min of 
reperfusion. Interestingly, the release of MMP2 into the coronary effluent of infarcted 
hearts was the same during baseline aerobic perfusion and after 30 min of global 
ischaemia; the significance of this is not entirely clear. One alternative explanation may 
be that the number of hearts used was too small to detect any change in activity level. 
The other possible reason is that there may already be maximal activation of MMP2 
with the initial infarction, so that subsequent ischaemia did not have any further effects 
on MMP2 activation.  
In conclusion, the data presented in this chapter showed that in infarcted hearts, baseline 
MMP2 activity during aerobic perfusion was significantly higher compared to either 
normal or sham hearts. When subjected to another global ischaemic insult, although 
there was no further increase in myocardial MMP2 activity during reperfusion, there 
was significant impairment in the recovery of mechanical function of the hearts. 
Increased MMP2 activity during baseline perfusion could be the culprit of heart 
dysfunction seen here. If MMP2 is indeed a contributory factor, inhibition of MMP2 
should ameliorate the heart dysfunction. This formed the basis of investigation in the 
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6 THE EFFECTS OF PHARMACOLOGICAL MMP2 
INHIBITION 
6.1 Introduction 
The data presented in the preceding chapter established the temporal profile of 
myocardial MMP2 activity in infarcted hearts during a subsequent acute ischaemia-
reperfusion period. During this insult, there was detrimental effect to the recovery of the 
mechanical function of the infarcted hearts compared to normal or sham, making the 
previous infarction an independent variable in causing a degree of dysfunction. MMP2 
activity was simultaneously shown to be elevated in infarcted hearts compared to 
normal or sham hearts during the subsequent acute ischaemia-reperfusion period, 
raising the possibility of MMP2 as a contributory factor to the mechanical dysfunction 
seen. To determine the possibility of a causal relationship, pharmacological inhibition of 
MMP2 activity may ameliorate myocardial dysfunction.  
MMP inhibition could be targeted with different strategies 124. The endogenous 
inhibitor, TIMP, is a potential candidate but it is difficult to control the balance between 
MMP/TIMP activities. Besides, TIMP binds with different rate and affinity to different 
MMPs and the control of these are difficult to achieve. TIMP may also activate some 
MMPs, rather than inhibiting it; TIMPs are more than just endogenous MMP inhibitors, 
they are bioactive molecules that can affect processes such as cell growth and death 
independently from its inhibitory actions on MMPs 12. In terms of exogenous inhibitors, 
first generation synthetic inhibitors of MMPs, such as batimastat, are small molecules, 
which are potent broad inhibitors; the mechanism of inhibition is via its zinc-chelating 
ability. Improved characterisation of the structure of MMPs with crystallography 
allowed more refined second and third generation inhibitors to be synthesised. Even so, 
clinical trials using these inhibitors for example prinomastat, mainly in cancer trials, 
were disappointing 122, 123, 125. The main problem with MMP inhibitors in clinical trials 
was disabling musculoskeletal side effects experienced by many patients, resulting in 
early termination of these trials. Besides, the inhibitors tested were broad inhibitors and 
it was thought that perhaps protective effects of MMPs such as repression of tumour 
angiogenesis may have also been indiscriminately inhibited.  
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Besides the synthetic inhibitors, the tetracycline family of antibiotics, have been shown 
to inhibit MMPs. Of this family of antibiotics, doxycycline is a good example and has 
been used extensively. Doxycycline is a commonly used antibiotic to treat various 
bacterial infections, with a long history of clinical use and good safety margins. 
Doxycycline is the most potent MMP inhibitor of the tetracycline family of antibiotics 
126. The mechanism of MMP inhibition is independent of its antibacterial action, namely 
via the metal ion (zinc and calcium) β-diketone moiety 127. It inhibits enzyme activity 
by chelating the active Zn2+ ion. Currently, a sub-antimicrobial dose of doxycycline is 
the only MMP-inhibitor approved by the Food and Drug Agency (FDA) for clinical use. 
In cardiovascular diseases, there are numerous studies of long-term LV remodelling 
using doxycycline as a MMP inhibitor 46-49, 51. Doxycycline was also shown to be an 
effective MMP2 inhibitor in experimental studies of acute ischaemia-reperfusion injury 
35, 38. Doxycycline makes a compelling choice for our experimental studies, due to the 
ease of translating its use as MMP2 inhibitor from bench to bedside, if our data 
supported its cardioprotective effect in this setting of acute ischaemia-reperfusion. 
There would be no need to conduct Phase I trials to determine safety of the drug.  
In order to establish any causal relationship between MMP2 and mechanical 
dysfunction seen in the infarcted hearts following global ischaemia, we also consider 
other alternative inhibitors. The primary consideration in choosing the second inhibitor 
was that it has to be an established inhibitor, with effective inhibition demonstrated 
experimentally. The primary goal is to enable us to demonstrate proof-of-principle 
regarding the role of MMP2 in this experimental setting of acute ischaemia-reperfusion. 
Hence, we decided on using 1,10-phenanthroline. It is again a commonly used MMP 
inhibitor in many studies 35, 38, 128, with proven effectiveness in inhibiting MMP2. 1,10-
phenanthroline is a heterocyclic organic compound that inhibits MMPs by chelating the 
Zn2+ ion and rendering the enzyme inactive. The chelating and enzyme inhibitory 
effects were first observed in carboxypeptidase A 129. The inhibition is fully reversible 
on dilution or addition of Zn2+ ions. It has a much lower affinity for calcium.  
The final part of these studies was to demonstrate that any improved mechanical 
function in isolated hearts, with addition of MMP inhibitor in the perfusate, was 
associated with biochemical evidence of reduced myocardial MMP2 activity. It is not 
possible to carry out a tissue assay of MMP2 activity when 1,10-phenanthroline is 
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present as it is a reversible inhibitor and the process of tissue extraction will dissociate 
the complexes formed and reverse the inhibitory action of 1,10-phenanthroline. 
Therefore, it was crucial to find an irreversible inhibitor to perform this aspect of the 
study, and one such agent [a commercially available MMP2/MMP9 inhibitor V, 444285 
(4-(4-(Methanesulfonamido)phenoxy)phenylsulfonyl)methylthiirane] was sourced from 
Calbiochem (Nottingham, UK); it is a cell-permeable compound, with enhanced 
aqueous solubility and improved selectivity for MMP2 (Ki =16 nM for MMP2, much 
higher for other MMPs). In a comparison study of different synthetic MMP inhibitors, 
444285 was found to be a potent irreversible MMP2 inhibitor 130. We conducted an 
initial dose-response study with 444285 to determine an optimal concentration, and 
subsequently, carried out a myocardial activity assay to determine if any improved 
recovery was due to biochemical myocardial inhibition of MMP2 activity. 
 
6.2 Methods  
6.2.1 Effect of doxycycline in normal hearts subjected to acute ischaemia-
reperfusion injury 
Adult, male Wistar rats (250-350g) (n=5-6/study) were perfused using the isolated 
Langendorff heart perfusion as described in Chapter 2, Section 2.2. The hearts were 
equilibrated for 20 min with aerobic perfusion, followed by 30 min of global 
normothermic ischaemia (induced by clamping of the aortic in-flow line). Subsequently, 
the hearts were reperfused for a further 60 min with aerobic perfusion. Two treatment 
groups were examined with different protocols of 100 µM doxycycline treatment (Fig 
6.1), and they were compared to a historical control group of normal hearts (defined as 
Group i in Fig 6.1) carried out in studies described in Chapter 4 with the same perfusion 
durations. The doxycycline concentration of 100 µM was used as it had been 
demonstrated in other studies to be effective in inhibiting MMP2, using a similar model 
and perfusion protocol 35, 38. In Group ii, doxycycline was used as a pre-treatment prior 
to global ischaemia, by adding it to the perfusate during the last 10 min of aerobic 
perfusion. In Group iii, doxycycline was added as both a pre- and post-treatment, i.e for 
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10 min before and after ischaemia. This was a common protocol used in other 
experimental isolated heart perfusion models of acute ischaemia-reperfusion studies.  
 
Figure 6.1 Langendorff perfusion protocol with addition of doxycycline. 
Group i consisted of historical control normal hearts, perfused in studies carried out 
in Chapter 4 and compared with Group ii and Group iii, perfused in this Section, with 
the addition of doxycycline to the perfusate as shown. 
The HR, LVDP and LVEDP was monitored and acquired continuously throughout the 
perfusion protocol. The recovery of LVDP was measured as a % recovery of its pre-
ischaemic value. The recovery profile during the reperfusion period was compared to 
isolated heart perfusion of normal hearts that was carried out in Chapter 4. Historical 
control group was used to minimise the number of animals used in the experiments and 
to be compliant to the 3R principles set out in the Handbook of Laboratory Animal 
Management and Welfare 131. The experiments for the historical control group were 
only carried out once I was completely competent with the technique, and the interval 
between the historical control experiments and these experiments was within 9 months. 
The recovery profile of each group was analysed using 2-way repeated measures 
ANOVA. The mean final LVDP recovery between the groups was also compared using 
ANOVA and post-hoc analysis by means of Tukey’s test (for multiple comparisons). A 
value of p<0.05 was considered statistically significant. 
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6.2.2 Effect of 1,10-phenanthroline in hearts subjected to acute ischaemia-
reperfusion injury 
Adult, male Wistar rats (250-350 g) were used in these experiments. Four groups of 
hearts (n=5-6/group) were perfused by isolated Langendorff heart perfusion as 
described in Chapter 2, Section 2.2. As above, Group i consisted of normal hearts and 
Group iii was infarcted hearts perfused by isolated Langendorff heart perfusion with 20 
min of aerobic equilibration, followed by 30 min of global ischaemia and 60 min of 
reperfusion as described Chapter 4. Group ii was hearts harvested from normal male 
rats (normal hearts) and Group iv was hearts harvested from male rats where the LAD 
was ligated 7 days prior to Langendorff perfusion. The anaesthesia and surgical 
procedure performed was as described in Chapter 2 Section 2.1. During isolated 
Langendorff perfusion, the hearts were first equilibrated with aerobic perfusion for 20 
min, followed by 30 min of global normothermic ischaemia (induced by clamping of 
the aortic inflow line). Subsequently the hearts were reperfused aerobically for 60 min 
(Fig 6.2). 1,10-phenanthroline (100 µM) was added to the perfusate 10 min before and 
after ischaemia. This protocol and drug concentration was shown in previous studies to 
be effective in inhibiting MMP2 35.  The HR, LVDP and LVEDP was monitored and 
acquired continuously throughout the perfusion protocol. CF was measured every 10 
min during the perfusion period. The recovery of LVDP was expressed as a % recovery 
of its pre-ischaemic value. The recovery profile during the reperfusion period was 
compared to isolated heart perfusion of equivalent normal and infarcted hearts from 
studies described in Chapter 4, again as an effort to reduce the number of animals used 
in the study. The recovery profile was analysed using the exponential association curve. 
The mean final LVDP recovery between the groups with and without 1,10-
phenanthroline was also compared using unpaired Student’s t-test (Group i vs Group ii 
and Group iii vs Group iv).  A value of p<0.05 was considered statistically significant. 
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Figure 6.2 Langendorff perfusion protocol in normal and infarcted hearts, with 
addition of 1,10-phenanthroline. 
Group i and Group iii were historical control groups, consisting of normal and 
infarcted hearts respectively that were perfused in studies described in Chapter 4. 
These groups were compared to Group ii and Group iv respectively. 
 
6.2.3 Effect of 444285, a specific MMP2/MMP9 inhibitor, in infarcted hearts 
subjected to acute ischaemia-reperfusion injury 
Adult, male Wistar rats (250-350 g) were used (n=4-6/group). The rats were subjected 
to LAD ligation as described in Chapter 2, Section 2.1 and subsequently perfused in 
isolated Langendorff mode as described in Chapter 2, Section 2.2. During isolated 
Langendorff perfusion, the hearts were first equilibrated with aerobic perfusion for 20 
min, followed by 30 min of global normothermic ischaemia (by clamping of the aortic 
inflow cannula) and subsequently 60 min of reperfusion (Fig 6.3). The HR, LVDP and 
LVEDP were monitored and acquired continuously.  
 
Figure 6.3 Langendorff perfusion protocol in infarcted hearts, with addition of 444285 
at 50, 100, and 150 nM 10 min pre- and post-ischaemia. 
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To our knowledge, there are currently no published studies (either in isolated hearts or 
in vivo models) using 444285 as MMP2 inhibitor; therefore, we conducted a dose-
response study of possible concentrations of 444285 based on the enzyme dissociation 
constant (Ki) of 444285, which is 16 nM. The starting concentration should be at least 
three-fold higher than the Ki of 444285; hence 50, 100 and 150 nM were used. The 
inhibitor was added to the perfusate 10 min before and after global ischaemia (Fig 6.3). 
The CF was measured every 10 minutes during reperfusion. The recovery of LVDP was 
expressed as % pre-ischaemic value. The recovery profile during the reperfusion period 
was compared to isolated heart perfusion of infarcted hearts as carried out in Chapter 4, 
Section 4.2. The recovery profile was analysed using the exponential association curve. 
The mean final LVDP recovery between the groups was also compared using one-way 
ANOVA and post-hoc test by means of Dunnett’s test (for multiple comparisons).  A 
value of p<0.05 was considered statistically significant. 
 
6.2.4 Effect of 444285 on myocardial MMP2 activity in infarcted hearts 
subjected to acute ischaemia-reperfusion. 
Adult, male (250–350 g) Wistar rats were used in this experiment. The rats were 
subjected to LAD ligation as described in Chapter 2, Section 2.1. All the animals were 
recovered for 7 days, with free access to food and water. After 7 days, the infarcted 
hearts were harvested from the animal and perfused in the isolated Langendorff heart 
perfusion as described in Chapter 2, Section 2.2. Two groups of hearts were compared 
in this study. The perfusion protocol was as described in Section 6.2.3 and depicted in 
Fig 6.3. Group 1 hearts were perfused without 444285 whilst Group 2 hearts were 
perfused with the optimal dose of 444285 that produced maximal recovery during 
reperfusion based on the dose response study carried out in Section 6.2.3. This optimal 
dose was added to the perfusate 10 minutes before and after global ischaemia (based on 
the data obtained in Section 6.3.3). The aim of using 444285 was to attempt to 
demonstrate biochemical evidence of myocardial MMP2 activity inhibition, which 
contributes to improved mechanical recovery of isolated hearts after ischaemia. 
The hearts were freeze-clamped with liquid nitrogen at different time points [after 20 
min of aerobic perfusion, after ischaemia (0’), 2 min of reperfusion (2’), 5 min of 
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reperfusion (5’) and 10 min of reperfusion (10’)] during reperfusion (as in Section 
5.2.1) (n=4 in each group at each time point). The hearts were stored at -80°C until use. 
The hearts were homogenised with lysis buffer as described in Chapter 2, Section 2.3. 
The supernatant was collected and used to assess MMP2 activity using MMP2 activity 
assay (GE Healthcare, Amersham, UK). The activity assay was carried out as described 
in Chapter 2, Section 2.7. Protein assay was also carried out to determine the protein 
content in the supernatant as described in Chapter 2, Section 2.4. The result of MMP2 
activity assay was expressed as ng/ml/g of protein. Mean MMP2 activity at different 
times in each group was compared using ANOVA, with post-hoc Tukey’s test for 
multiple comparisons. Mean MMP2 activity at each time point between infarcted hearts 
without and with 444285 treatment were compared using Student’s t-test. A value of 
p<0.05 was considered significant.  
 
6.3 Results   
6.3.1 Effect of doxycycline in normal hearts subjected to acute ischaemia-
reperfusion injury 
 
The baseline parameters of HR, LVDP and LVEDP for all 3 groups are shown in Table 
6.1. 
Table 6.1 Baseline parameters (HR, LVDP and LVEDP) obtained after aerobic 
perfusion in Group i (historical control group), Group ii (pre-treatment with 
doxycycline) and Group iii (pre- and post-treatment with doxycycline). In groups 
where doxycycline was added to the perfusate, the parameters were obtained prior to 
the addition of doxycycline. 







HR (beats/min) 300±24 286±8 274±6 p=0.45 
LVDP (mmHg) 119±5 132±5 134±5 p=0.14 
LVEDP (mmHg) 3±2 3±1 6±1 p=0.12 
 
 
The addition of doxycycline to the perfusate affected the HR and LVDP, but not the 
LVEDP (Fig 6.4). The mean HR decreased significantly from 278±5 beats/min to 
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227±9 beats/min (Fig 6.4i) (p=0.0001) and the mean LVDP decreased from 133±4 
mmHg to 126±4 mmHg (Fig 6.4ii) (p=0.02) after the addition of doxycycline to the 









Figure 6.4 Graphs showing the change in (i) HR, (ii) LVDP and (iii) LVEDP before and 
10 min after addition of doxycycline in the perfusate during aerobic perfusion of 
normal hearts. n=11. § p=0.0001, * p=0.02 
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There was slow and gradual recovery of the LVDP in all groups throughout the 
reperfusion period (Fig 6.5). However, recovery in hearts perfused with doxycycline 
(Groups ii and iii) was slower compared to the normal hearts (Group i) perfused in 
studies described in Chapter 4, Section 4.3.2.  
 
 
 Figure 6.5 Recovery profile of LVDP in normal hearts during reperfusion after 30 min 
global ischaemia, without and with addition of doxycycline to the perfusate.  
Group i: Control normal hearts, n=5; Group ii: Normal hearts perfused with 100 µM 
doxycycline during the last 10 min of aerobic perfusion, n=6; Group iii: Normal hearts 
perfused with 100 µM doxycycline for 10 min before and 10 min after ischaemia, n=6. 
* p<0.05 
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The recovery of LVDP in Group (i) reached a plateau towards the end of the reperfusion 
period, but the recovery of LVDP in the hearts in Groups (ii) and (iii) seemed to be 
increasing still, even at the end of perfusion. From 40 min of reperfusion onwards, the 
recovery of LVDP in Group (iii) was significantly lower compared to Group (i) 
(p<0.05). The final recovery achieved (% pre-ischaemic LVDP) was 39±5%, 30±4% 
and 21±7% (p=0.1) in Groups (i), (ii) and (iii) respectively. 
The recovery of HR in hearts perfused in Group (iii) was also slower compared to 
control [Group (i) or Group (ii)], before reaching a plateau at 30 minutes of reperfusion 
(Fig 6.6). During the first 10 min of reperfusion, the HR recovery was significantly 
(p<0.05) worse in Group (iii) compared to Group (i). However, with time, the recovery 
of HR eventually converged and at the end of reperfusion, there was no difference in the 
recovery between the groups.  
 
 
Figure 6.6 Recovery profile of HR in normal hearts during reperfusion after 30 min 
global ischaemia without and with addition of doxycycline to the perfusate . * p<0.05 
Group i: Control normal hearts, n=5; Group ii: Normal hearts perfused with 100 µM 
doxycycline during the last 10 min of aerobic perfusion, n=6; Group iii: Normal hearts 
perfused with 100 µM doxycycline for 10 min before and 10 min after ischaemia, n=5. 
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Recovery of CF, too, was worse in Group (iii) compared to Group (i), especially within 
the first 10 min of reperfusion, eventually converging to equivalent recovery at the end 
of reperfusion (Fig 6.7).  
 
 
Figure 6.7 Recovery profile of CF in normal hearts during reperfusion after 30 min 
global ischaemia without and with addition of doxycycline to the perfusate.  The first 
CF measurement was taken during the first min of reperfusion immediately after 
global ischaemia. * p<0.05 
Group i: Control normal hearts, n=5; Group ii: Normal hearts perfused with 100 µM 
doxycycline during the last 10 min of aerobic perfusion, n=6; Group iii: Normal hearts 
perfused with 100 µM doxycycline for 10 min before and 10 min after ischaemia, n=5. 
 
 
As for LVEDP, there was no difference in LVEDP between all 3 groups throughout the 
60 min reperfusion period (Fig 6.8). 




Figure 6.8 Recovery profile of LVEDP in normal hearts during reperfusion after 30 min 
global ischaemia. 
Group i: Control normal hearts, n=5; Group ii: Normal hearts perfused with 100 µM 
doxycycline during the last 10 min of aerobic perfusion, n=6; Group iii: Normal hearts 




As the above data showed, doxycycline, in our study, did not result in any beneficial 
effects, especially in improving LVDP recovery during reperfusion. In fact, recovery of 
LVDP was worse when doxycycline was added to the perfusate before and after 
ischaemia. We therefore decided not to proceed with using doxycycline as the MMP2 
inhibitor in infarcted hearts as we did not anticipate any improvement in 
cardioprotection of the infarcted hearts.  
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6.3.2 Effect of 1,10-phenanthroline in hearts subjected to acute ischaemia-
reperfusion injury 
The addition of 100 µM 1,10-phenanthroline to the Krebs-Henseleit perfusate solution 
significantly changed the physiological parameters during equilibration aerobic 
perfusion of the infarcted hearts when infused into the hearts (Fig 6.9). The parameters 
were measured after 10 min of aerobic equilibration (before starting the infusion of 
1,10-phenanthroline) and again after 10 min of infusion of 1,10-phenanthroline (before 
the start of global ischaemia).  
 
Figure 6.9 Representative recording taken from LabChart during Langendorff 
perfusion, with addition of 1,10-phenanthroline. 
Recording taken from LabChart during Langendorff perfusion, showing the decrease 
in LV pressure measured at the onset of the infusion of 1,10-phenanthroline, as 
marked by the arrow. 
 
Thus, LVDP decreased significantly (p=0.02) from a mean of 127±12 mmHg to 86±5 
mmHg, the heart rate was decreased significantly (p=0.0005) from 285±13 beats/min to 
173±13 and LVEDP was significantly (p=0.009) increased (Fig 6.10). 











Figure 6.10 Changes in (i) LVDP, (ii) HR and (iii) LVEDP during isolated Langendorff 
perfusion before and after infusion of 1,10-phenanthroline, during aerobic 
equilibration, n=5. 
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With 1,10-phenanthroline treatment before and after ischemia in both normal (Group ii) 
and infarcted (Group iv) hearts, there was rapid recovery of LVDP, which plateaued by 






Figure 6.11 Functional recovery (LVDP) in normal and infarcted hearts, with and 
without 1,10-phenanthroline. 
(i) Recovery profiles of LVDP and (ii) final LVDP recovery in normal (N) and infarcted 
(I) hearts, with and without 1,10-phenanthroline (Phen). n=5 N, n=6 N+Phen, n=6 I and 
n=5 I+Phen. * p=0.05 N vs N+Phen, § p=0.0002 I vs I+Phen 
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Comparison of these 1,10-phenanthroline treated hearts with the equivalent normal 
(Group i) and infarcted (Group iii) hearts (as described in Chapter 4) showed that 1,10-
phenanthroline treatment significantly (p<0.05) improved recovery in both groups (Fig 
6.11i). The final recovery of LVDP achieved in normal hearts and infarcted hearts 
treated with 1,10-phenanthroline was 63±5% and 47±4% respectively, which was 
significantly higher compared to the equivalent hearts perfused without MMP inhibition 
(p=0.01 in normal hearts and p=0.0002 in infarcted hearts). Interestingly, the final 
recovery of infarcted hearts treated with 1,10-phenanthroline was similar to untreated 
normal hearts by 60 minutes of reperfusion (Fig 6.11ii) but 1,10-phenanthroline 
treatment increased the rate of recovery (after the 1,10-phenanthroline perfusion). 
 
6.3.3 Effect of 444285, a specific MMP2/MMP9 inhibitor, in infarcted hearts 
subjected to acute ischaemia-reperfusion injury 
With the addition of 444285 to the perfusate, both 100 nM and 150 nM significantly 
decreased the HR compared to prior to the addition of the drug (100 nM, p=0.002 and 
150 nM, p=0.005) (Fig 6.12i). All 3 concentrations of 444285 did not alter LVDP or 
LVEDP of the hearts during aerobic perfusion (Fig 6.12ii and 6.12iii). Unfortunately, as 
parallel heart perfusions were carried out, it was not logistically feasible to measure 
coronary flow before and after infusion of 444285. However, comparison of coronary 
flow at each concentration of 444285 with coronary flow in control infarcted hearts (as 
described in Chapter 4) showed that coronary flow in control infarcted hearts without 
any addition of 444285 was significantly (p<0.0001) lower compared to when 50 nM, 
100 nM or 150 nM of 444285 was added to the perfusate during the last 10 min of 
aerobic perfusion (8.7±0.5 mls/min vs 13.4±1 mls/min, 16±0.6 mls/min and 14±1 
mls/min, respectively) (Fig 6.13). At 100 nM, the CF was also significantly (p<0.0001) 
higher compared to CF when infarcted hearts were perfused with 100 µM of 1,10-
phenanthroline. 










Figure 6.12 Graphs showing the changes in (i) HR, (ii) LVDP and (iii) LVEDP before 
and after infusion of different concentration of 444285. Solid bar graph – pre-infusion, 
Clear, striped bar graph – post-infusion. n=5 in 50 nM, n=6 in 100 nM and n=6 in 150 
nM  
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Figure 6.13 Graph showing coronary flow measured after 20 min of aerobic perfusion 
in infarcted hearts and coronary flow measured in infarcted hearts after 10 min of 
perfusion with the addition of 50 nM (n=5), 100 nM (n=6), 150 nM (n=6) of 444285 and 
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During ischaemia, there was no difference in the contracture parameters between 
infarcted hearts perfused with or without 444285 (Table 6.2). 
Table 6.2 Contracture parameters (time to contracture, peak and time to peak) in 
infarcted, and infarcted hearts perfused with addition of 444285 at 50 nM, 100 nM and 
















61±8 52±9 61±8 51±6 
(p=0.33) 
Time to peak 
(min) 
17.7±0.7 20.4±0.5 19.2±1.1 18.5±0.7 
(p=0.16) 
 
The recovery of LVDP during the first 30 min of reperfusion between different 
concentrations of 444285 was similar to each other and to infarcted hearts without 
444285 (Fig 6.14i). However, after 40 min of reperfusion, the recovery of LVDP in 
infarcted hearts perfused with and without 444285 started to diverge. The recovery 
profile of the groups was significantly (p<0.0001) different compared to equivalent 
hearts without 444285. The final recovery achieved in the 100 nM group at 32±2% was 
significantly (p=0.02) higher (22±2%) than infarcted hearts perfused without 444285 
(Fig 6.13ii). 







Figure 6.14 Recovery profile of (i) LVDP and (ii) final LVDP recovery in infarcted 
hearts perfused with 50 nM (n=5), 100 nM (n=6) and 150 nM (n=6) of 444285 compared 
to infarcted hearts (n=6) from studies described in Chapter 4. *p<0.05 
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As for the HR, the groups perfused with 444285 had a gradual recovery before reaching 
a plateau at 30 min of reperfusion, which contrasted slightly with the infarcted hearts 
perfused without 444285, where the peak maximal recovery was reached at 20 min of 
reperfusion, before plateauing to a lower value (Fig 6.15).  
 
  
Figure 6.15 Recovery of HR in infarcted hearts perfused with 50 nM (n=5), 100 nM 
(n=6) and 150 nM (n=6) of 444285 compared to infarcted hearts (n=6) previously 
perfused without 444285 in Chapter 4.  
 
The profile of recovery of LVEDP and CF of all groups followed a very similar course 
(Fig 6.16). 







Figure 6.16 The recovery profile of (i) LVEDP and (ii) CF in infarcted hearts perfused 
with 50 nM (n=5), 100 nM (n=6) and 150 nM (n=6) of 444285 compared with infarcted 
hearts (n=6) without 444285 described in Chapter 4. The first CF measurement was 
taken during the first min of reperfusion after global ischaemia.  
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6.3.4 Effect of 444285 on myocardial MMP2 activity in infarcted hearts 
subjected to acute ischaemia-reperfusion 
In Group 1 (infarcted hearts without addition of 444285), MMP2 activity peaked after 
30 min of global ischaemia before gradually decreasing back to its baseline value.  
 
 
Figure 6.17 MMP2 activity in infarcted hearts perfused with or without 100 nM of 
444285 at baseline aerobic perfusion, after global ischaemia (0 min) and at 2, 5 and 10 
min of reperfusion (n=4 in each group at each time point). ψ  p<0.0001 vs other 
sampling times in infarcted hearts without 444285, ∗  p=0.02 vs MMP2 activity in 
infarcted hearts without 444285 immediately after global ischaemia, ∞  p=0.047 vs 
MMP2 activity in infarcted hearts without 444285 at 10 min reperfusion. 
 
The peak of MMP2 activity immediately after global ischaemia was significantly 
(p<0.0001) higher compared to the other time points assessed (Fig 6.17). When 444285 
was added to the perfusate 10 min before and after ischaemia (Group 2), the trend of 
MMP2 activity was similar to hearts in Group 1; there was a smaller peak immediately 
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after ischaemia, but this was not significantly higher compared to the other time points, 
unlike in Group 1. However, MMP2 activity immediately after global ischaemia in 
Group 2 was significantly (p=0.02) lower compared to the activity in hearts in Group 1. 
After 10 min of reperfusion, MMP2 activity in infarcted tissues perfused with 444285 
was also significantly (p=0.047) lower compared to hearts perfused without 444285.  
 
6.4 Discussion  
There have been a number of studies investigating the effects of MMP inhibitors on 
isolated perfused rat hearts subjected to ischaemia-reperfusion 35, 36, 38, 79, 128. In an 
experimental in-vitro setting, Cheung and co-workers demonstrated that there was 
improved recovery of mechanical function (using rate-pressure product as the index of 
function) of isolated hearts subjected to acute ischaemia-reperfusion when doxycycline 
(at different concentrations ranging from 10 µM to 100 µM) was added to the perfusate 
35. In contrast, we were unable to confirm these results with a doxycycline concentration 
of 100 µM (the optimal dose established by Cheung and colleagues 35), with no 
significant improvement in the recovery of LV function of isolated hearts in our studies 
(Section 6.3.1). There are a few fundamental differences in the 2 studies, which may 
explain the results. In our study, we used a global ischaemic duration of 30 min 
compared to a 20 min duration used in Cheung’s study. An additional 10 min may be 
sufficient to alter the capacity of the heart to recover, as previously shown in Chapter 4, 
Section 4.3. The index of mechanical function and recovery was different between the 2 
studies; we use % recovery of LVDP compared to its baseline pre-ischaemic values, 
whereas the rate-pressure product was the index used by Cheung and co-workers. The 
mode of delivery of doxycycline differed in that constant pressure was used in our 
studies, in contrast to constant flow. This may be crucial, especially in the early 
reperfusion phase when coronary flow was usually depressed. Collectively, these subtle 
differences may explain the results obtained in our study. In a rabbit model of isolated 
heart perfusion, Donato and colleagues looked at the role of MMP2 in ischaemic post-
conditioning on the heart 132. They found that ischaemic post-conditioning decreased 
infarct size in the heart, with inhibition of MMP2 activity. This decrease in infarct size 
was duplicated when doxycycline, at a concentration of 50 µM, was administered to 
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hearts without post-conditioning, and the extent of reduction of infarct size was similar 
to ischaemic post-conditioning. However, in their experiments, although zymographic 
analysis showed that there was decreased MMP2 activity in the coronary effluent and 
ventricular tissues within 2 min of reperfusion in hearts that underwent post-
conditioning protocol and hearts reperfused with doxycyline, there was no observed 
improvement in the functional recovery (LVDP) of the heart. Hence, in vitro evidence 
of enzyme activity inhibition does not necessarily translate to functional recovery. 
These contradictory observations may be due to several unresolved issues regarding 
tetracyclines as MMP inhibitors. Although doxycycline is the most potent MMP 
inhibitor in this group, generally they are still relatively weak and broad, non-specific 
MMP inhibitors. The inhibitory constants of doxycycline are in the micromolar range 
compared to other potent inhibitors with inhibitory constants in nanomolar range 133.  
Nonetheless, the profile of recovery of LVDP in normal hearts perfused with 
doxycycline showed that recovery was still increasing at the end of the observed 60 min 
reperfusion period (Fig 6.5). It is possible that the method of delivery of doxycycline in 
our model resulted in a delayed recovery, and perhaps with longer reperfusion time i.e 
120 min, the recovery achieved may be equivalent to studies carried out by Cheung and 
associates. It is difficult to speculate. A longer reperfusion time also has its 
disadvantages, as the isolated heart will start to deteriorate 85. It is unlikely that they 
would show a beneficial effect, even with longer reperfusion period.    
In contrast, inhibition with another non-specific and reversible MMP inhibitor, 1,10-
phenanthroline, resulted in a rapid and much improved recovery in LVDP. In an effort 
to comply with the 3R principles of animal research (to reduce the number of animals 
used), dosage studies to determine the optimal dose for 1,10-phenanthroline were not 
carried out. The concentration selected was based on previous studies, which had 
demonstrated that 100 µM was an effective concentration for MMP inhibition 35, 38. Our 
studies were similar to other studies 35; infusion of perfusate containing 1,10-
phenanthroline significantly altered function. Cheung and colleagues also reported that, 
with infusion of 100 µM 1,10-phenanthroline, the rate-pressure product (used as an 
index of mechanical function in their study) was significantly depressed, but recovered 
once infusion of 1,10-phenanthroline was stopped.  Our study showed that LVDP was 
reduced and LVEDP increased, but once the infusion was stopped after 10 min, there 
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was rapid recovery of LVDP, as shown by the steep gradient of the recovery curve 
compared to equivalent controls. The effect on LVDP could be secondary to its Ca2+-
chelating actions. However, as it is a reversible inhibition, once the infusion was 
stopped, its effects were washed out with perfusion using regular KHB. The data 
suggested that even a short, reversible inhibition of MMP protected the hearts and 
resulted in improved functional recovery.  
Perfusion studies with a selective and irreversible inhibitor, 444285, further reinforced 
the role of MMP2 in cardiac dysfunction in infarcted hearts subjected to further global 
ischaemia. There was a dose-dependent improvement in recovery, with an optimal 
concentration of 100 nM. As this inhibitor has not been used in other isolated 
Langendorff heart perfusion studies (to our knowledge), the effects of the inhibitor on 
the physiological parameters were considered. The only striking difference was the 
significantly higher coronary flow in hearts perfused with 444285, at all 3 
concentrations tested. This is not surprising given the evidence available showing the 
vasoactive role of MMP2. The secretory profiles of MMP2 and MMP9 in 
microvasculature differed from macrovasculature 134. In cultures of bovine coronary 
arterial endothelial cells, active MMP2 decreased nitric oxide (NO) release in these cells 
in response to agonist stimulation 135. Additionally, selective inhibition of MMP2 
resulted in vasodilation of rat mesenteric arteries 136. Our data also showed that selective 
and irreversible inhibition of MMP2, even for a short duration of 10 min, was sufficient 
to inhibit MMP2-induced vasoconstriction. MMP2 activity assay provided evidence that 
improved functional recovery was associated with significant inhibition of myocardial 
MMP2 activity. The improvement in recovery profile and final recovery was not as 
good as MMP inhibition with σ-phenanthroline. This may be due to the fact that 444285 
does not inhibit MMP2 activation by MT1-MMP. MT1-MMP has been shown to be 
activated during ischaemia-reperfusion in the heart 42; MT1-MMP in turn activates 
MMP2 11. Hence, compared to 1,10-phenanthroline, the extent of MMP2 inhibition by 
444285 may be less.  
In summary, the data presented here showed the link between improvement in 
mechanical function of isolated hearts (normal and infarcted) subjected to acute 
ischaemia-reperfusion and molecular evidence of MMP2 inhibition, when the hearts 
were perfused with MMP2 inhibitors. MMP2 inhibition may be potential novel targets 
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or as adjuncts in cardioprotection of hearts during cardiac surgery. Cardiac surgery is a 
unique situation where global ischaemia and reperfusion of the heart is carried out in a 
controlled environment. This provides an excellent opportunity to introduce drugs at 
specific times, such as at the onset of ischaemia or at the start of reperfusion, that may 
alter enzyme or protein effects that are activated by ischaemia-reperfusion and may be 
detrimental to the recovery of function of the hearts. It also allows short-term treatment 
rather than longer-term treatment with drugs that may have potential side effects when 
taken over a longer period of time. Besides, as previously discussed in Chapter 1, 
enzymes such as MMPs may have beneficial effects, all depending on the timing from 
injury. This forms the basis of our investigation in the subsequent and final chapter. We 
want to investigate the effect of short-term MMP2 inhibition, used in conjunction with 
cardioplegia solution, in protecting the heart as would happen during cardiac surgery. 
We selected 1,10-phenanthroline as an addition to a standard cardioplegia solution, the 
St Thomas’ Hospital cardioplegia solution, as Section 6.3.2 and 6.3.3 showed that there 
was greater extent of recovery in the infarcted hearts treated with 1,10-phenanthroline 
compared to 444285.   
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7 THE INFLUENCE OF CARDIOPLEGIA (ST 
THOMAS HOSPITAL SOLUTION) WITH AND 
WITHOUT MMP INHIBITOR ON THE 
RECOVERY OF INFARCTED HEARTS  
7.1 Introduction 
The demographics of patients undergoing cardiac surgery have changed with time 70. 
The mean age of patients having isolated coronary artery bypass graft surgery (CABG) 
increased slightly from 63 years in 2000 to 66 years in 2008, but the proportion of >75 
years undergoing surgery more than doubled from 10% in 1999 to 25% in 2008. Crude 
mortality of patients over the age of 80 years undergoing isolated CABG was about five 
times higher compared to those under the age of 56 in 2008. The proportion of patients 
with significant coronary artery disease affecting the left main stem (LMS) of the left 
coronary artery has also doubled between 2001 and 2006, and these patients have 
double the mortality rate. There is also a changing trend in patients needing urgent or 
emergency CABG, increasing from 29.8% in 2001 to 32.9% in 2008.  The proportion of 
patients having surgery within a month of suffering from ACS increased from 19% in 
2004 to 34% in 2008. The mortality in patients having CABG within 6 hours of 
suffering an MI was 11.8%, but there was a stepwise decrease in operative mortality 
with increasing interval between MI and surgery, with mortality approaching that of 
elective surgery if MI was >90 days prior to surgery (Fig 7.1). The change in this trend 
probably reflects the change in management of patients presenting with ACS, as 
discussed in Chapter 1.  Often, patients with LMS disease are also patients requiring 
urgent or emergency surgery. These factors, when considered together, raise the risk 
profile of patients undergoing CABG. There is now an even greater need for improved 









Figure 7.1 Data from the 6th National Adult Cardiac Surgical Database Report 2008. 
The crude mortality rate according to the timing of the most recent MI. Highlighted 
boxes emphasised the decrease in mortality the longer the interval from MI to 
surgery. 
 
As previously mentioned (Chapter 1, Section 1.4), St Thomas’ Hospital cardioplegic 
solution is one of the most commonly used cardioplegic solutions during cardiac 
surgery and protects the heart reasonably well during cardiac surgery; however, it is not 
without certain disadvantages. Ongoing research into improving cardioprotection 
includes improving or supplementing St Thomas’ Hospital cardioplegic solution 55, 
other types of cardioplegia 57, 137 and also alternative means of cardioprotection besides 
chemical arrest of the heart, for example intermittent fibrillation of the heart 56. MMP2 
inhibition may play a role as a supplement to St Thomas’ Hospital cardioplegia solution 
due to a number of reasons. Firstly, inhibition of MMP2 may reduce its intracellular 
action on structural and functional proteins during acute ischaemia-reperfusion injury. 
MMP2 was shown to be activated by peroxynitrite, a substrate generated from oxidative 
stress injury to the heart 79; thus, inhibition of MMP2 may reduce the detrimental effects 
of oxidative stress. Lastly, appropriate inhibition of MMP2 may improve protection of 
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the coronary vasculature by its effects on the endothelium. It has been shown to have 
both vasocontrictive and vasodilatory effects 13. MMP2 can vasoconstrict arteries by 
acting on endothelin-1 (ET-1), producing a potent vasoconstrictor peptide 138 or by 
cleavage of calcitonin gene-related peptide (CGRP), which ameliorated the vasodilatory 
effects of CGRP 136. On the other hand, its vasodilatory effect is mediated by the 
inhibition of Ca2+ entry mechanism 13. 
Regarding the role of MMP2 in cardiac surgery, cardiopulmonary bypass and 
cardioplegia, there are various small studies that suggested a role for MMPs in causing 
cardiac dysfunction associated with cardiopulmonary bypass.  It is well-established that 
cardiopulmonary bypass (CPB) circuits invoke a systemic inflammatory response, with 
enhanced release and activation of neutrophils. Increased circulating neutrophils 
mediate the secretion of MMP9 into the circulatory system post-CPB, with significantly 
increased plasma levels and activity by 2 to 6 hours after weaning from CPB 139. Using 
a microdialysis technique combined with fluoroscopy, overall MMP activity was found 
to increase significantly with initiation of CPB, remained at the same level when cross-
clamp (ischaemic time) was started, decreased back to almost baseline with diastolic 
arrest of the heart, before increasing again with reperfusion and weaning from CPB 140. 
The decrease in MMP activity during mid-CPB time was thought to be secondary to the 
cardioprotective strategy, where hypothermic cardioplegia was used.  During and after 
CPB, there was a distinct pattern of increased MMP activity; MMP8 rapidly increased 
and then decreased after weaning from CPB, and there was similar increase in MMP13 
and MMP9 and return to baseline within 6 hours of weaning from CPB. In contrast, 
MMP2 increased between 6 and 24 hours after separation from CPB 141. The amount of 
MMP2 in atrial tissue at reperfusion correlated negatively with the function of the heart 
as measured by LV stroke work index (LVSWI) 142. The higher the amount of MMP2 
present, the poorer the function of the heart.  
I previously established the temporal profile of MMP2 (Chapter 5), with MMP2 activity 
in infarcted myocardium being significantly higher compared to normal or sham hearts. 
If these hearts are subsequently subjected to other distinct events (i.e. cardiopulmonary 
bypass and/or global no-flow ischaemia), that have been shown to independently 
activate MMP2 and was detrimental to the mechanical function of the heart, these 
events could have synergistic effects that will enhance the injury imposed on an already 
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stressed heart. MMP2 inhibition may indeed be a new strategy to protect a vulnerable 
myocardium perioperatively during cardiac surgery. 
MMPs have a wide range of biological actions, sometimes causing opposite effects of 
biological processes such as triggering cell apoptosis as well as cell proliferation and 
activating and inactivating cytokines and chemokines 122. As Barbara Fingleton puts it 
“the optimal use of MMP inhibitors hinges on identifying the deleterious MMP activity 
and targeting that while sparing any non-contributory or beneficial effects” 123. Hence, 
the timing and duration of MMP inhibition affects outcome. Pharmacological inhibition 
of MMP2 and MMP9 decreased the risk of cardiac rupture post-MI, but continued 
inhibition could be damaging as it prevented healing and ultimate resolution 43, 143.  
Hence, in this chapter, we explore the possibilities of short-term MMP2 inhibition as an 
adjunct to St Thomas’ Hospital cardioplegic solution, in improving cardioprotection of 
the infarcted myocardium. The timing of MMP2 inhibition was also explored using 
different isolated heart perfusion protocols. 
 
7.2 Methods  
Adult, male Wistar rats (250-350 g) (n=6/group) were used in these experiments. The 
animals were first subjected to surgical ligation of the LAD artery as described in 
Chapter 2, Section 2.1, and allowed to recover for 7 days. After 7 days, the hearts were 
harvested and perfused in an isolated Langendorff heart perfusion as described in 
Chapter 2, Section 2.2. During isolated Langendorff perfusion, the hearts were 
equilibrated for 20 min with aerobic perfusion, before global, normothermic ischaemia 
was induced by clamping the aortic inflow line for 60 min, followed by 60 min of 
reperfusion with oxygenated perfusate. St Thomas’ Hospital cardioplegic solution 
(composition in mM: NaCl 11; MgCl2 16; KCl 16; CaCl2 1.2 and NaHCO3 10; pH 7.8 
at 37°C) was used to arrest the heart at the start of ischaemia.  Preliminary studies were 
conducted to determine the appropriate ischaemic duration when using cardioplegic 
protection; the ischaemic period was initially extended to 40 min (multiple infusion of 
St Thomas’ Hospital cardioplegia for 2 min every 20 min). Using 3 infarcted hearts, the 
recovery of LVDP was about 60% of pre-ischaemic baseline value (Fig 7.2). Thus, I 
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decided to extend the period of global ischaemia to 60 min (infusion of cardioplegia for 




Figure 7.2 Recovery profile in infarcted hearts, arrested with St Thomas’ cardioplegia. 
(Top insert) Langendorff perfusion protocol of infarcted hearts, with hearts arrested 
using St Thomas’ cardioplegia and 40 min global ischaemia.  
(Bottom) LVDP recovery (% pre-ischaemic value) profile in infarcted hearts perfused 
according to the perfusion protocol depicted in top insert (n=3). 
The various protocols and infusion of cardioplegia solution and MMP inhibitor are 
shown in Fig 7.3. 1,10-phenanthroline (100 µM) was used in these experiments as it 
was shown in Chapter 6 that it resulted in the best recovery of mechanical function of 
the infarcted hearts.  
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Figure 7.3 Langendorff perfusion protocol in infarcted hearts, with St Thomas’ 
cardioplegia protection (n=6/group). 
All hearts arrested with STH2 cardioplegia (i & ii) or STH2+1,10-phenanthroline (iii, iv 
& v). 1,10-phenanthroline added in addition in (ii), (iii) and (v) as shown. 
 
In Group (i), the hearts were arrested with St Thomas’ Hospital cardioplegia solution 
only. In Group (ii), the hearts were arrested with St Thomas’ Hospital solution and 1,10-
phenanthroline was added to the KHB perfusate 10 min before and after ischaemia. In 
Group (iii), the hearts were arrested with St Thomas’ Hospital solution plus 1,10-
phenanthroline, and 1,10-phenanthroline was included in the KHB perfusate 10 min 
before and after ischaemia. In Group (iv), the hearts were arrested with St Thomas’ 
Hospital cardioplegia plus 1,10-phenanthroline. In Group (v), the hearts were arrested 
with St Thomas’ Hospital cardioplegia plus 1,10-phenanthroline, and 1,10-
phenanthroline was added to the perfusate during the first 10 min of reperfusion. These 
various combinations of cardioplegia with 1,10-phenanthroline was used to determine if 
the presence of MMP inhibition during the various phases of ischaemia-reperfusion will 
impact the recovery of the hearts during reperfusion.  
The HR, LVDP and LVEDP were monitored and acquired continuously throughout the 
protocol. CF was measured every 10 min during the reperfusion period. The recovery of 
LVDP was expressed as % recovery of its pre-ischaemic value. The recovery profile 
during reperfusion phase was analysed using the exponential association curve analysis 
and 2-way repeated measures ANOVA of % LVDP recovery was also carried out. The 
final LVDP recovery at the end of 60 min reperfusion was compared between the 
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groups with one-way ANOVA and post-hoc Tukey’s test was performed (for multiple 
comparisons). A value of p<0.05 was considered statistically significant.  
 
 
7.3 Results  
7.3.1 Ischaemic contractures 
The parameters for ischaemic contracture are shown in Fig 7.4. During ischaemia, the 
time to onset of contracture for hearts in each group was (i) 32±3.2 min, (ii) 25±1.0 min, 
(iii) 35±0.2 min, (iv)29±3.0 min and (v)32±2.0 min, respectively (Fig 7.4i). Group (ii) 
developed contracture significantly (p=0.02) earlier than the hearts in Group (iii). The 
times taken for peak contracture to develop were 49±1.5, 42±1.0, 49±1.0, 45±3.0, and 
42±0.8 min, in Groups (i) to (v) respectively (Fig 7.4ii). Groups (ii) and (v) reached 
peak contracture significantly (p=0.009) earlier compared to Group (i). Peak contracture 
reached in the hearts in each group were 34±5, 50±4, 33±3, 50±6 and 50±4 mmHg, 
respectively; however, there were no statistically significant differences between the 














Figure 7.4 Contracture parameters in the each group during ischaemia (n=6/group). 
*p=0.02, § p=0.009 
 
7.3.2 Haemodynamic recovery 
The LVDP recovery profiles of each group of hearts were significantly (p<0.0001) 
different (Fig 7.5). The recovery of LVDP in Groups (i) and (iv) were the most rapid, 
recovering within the first 10 min and reaching a plateau by 20 min of reperfusion. On 
the other hand, recovery rates in the first 10 min in Groups (ii) and (iii) were slower 
before accelerating between 10 and 20 min of reperfusion. This observation was 
expected, secondary to the effect of 1,10-phenanthroline as previously found in Chapter 
6, Section 6.3.2. The recovery in Group (v) was the worst, with a much slower rate 
throughout reperfusion. At 20 and 30 min of reperfusion, LVDP recovery was 
significant better in Group (iii) compared to Group (v) (51±10% vs 18±3%, p<0.01; 
56±8% vs 27±3%, p<0.05). The final recovery of LVDP was 47±10%, 45±7%, 57±6%, 
39±5% and 36±4% in groups (i), (ii), (iii), (iv) and (v) respectively; these values did not 
reach statistical significance.  






Figure 7.5 Functional recovery in infarcted hearts, with St Thomas’ cardioplegia 
protection (n=6/group). 
LVDP recovery profiles in all groups during reperfusion after 60 min of global 














Figure 7.6 Recovery profiles of (i) HR, (ii) LVEDP and (iii) CF of the different groups 
infarcted hearts during reperfusion after 60 min of global ischaemia (n=6/group). First 
CF measurement taken during the first min of reperfusion after global ischaemia.  
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The recovery of HR in the different groups was similar, converging at 60 min of 
reperfusion to a recovery of between 70% to 80% of the pre-ischaemic value (Fig 7.6i). 
The recovery of LVEDP in all groups also followed a very similar trend, with increased 
LVEDP during the first 10 min of reperfusion, which subsequently declined but 
remained significantly higher than the pre-ischaemic value (Fig 7.6ii). Recovery of CF 
showed a slightly divergent trend; groups (i) to (iii) were fairly consistent, reaching a 
final recovery of about 50% of the pre-ischaemic value (Fig 7.6iii). However, Groups 
(iv) and (v) had a slightly lower final recovery of between 40-45%. 
Finally, we also considered the volume of cardioplegia infused in all the groups. The 
total volume, although slightly higher in Group (iii) at 28.1±3.6 ml, was not 
significantly different between the groups (Fig 7.7i). The volumes of cardioplegia was 
further analysed by dividing the total into first and second infusions. For the initial 
infusion at the onset of ischaemia, the volume of cardioplegia infused was significantly 
(p=0.02) higher in Group (v). However, the volume of second infusion of cardioplegia 






















Figure 7.7 Volume of cardioplegia infused (i) total, (ii) first infusion at the start of 
ischaemia and (iii) second infusion during mid-ischaemia (n=6/group). * p<0.02, § 
p<0.03 
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7.4 Discussion 
The evidence relating to the effects of cardioplegic protection on activity of MMPs is 
sparse, and especially the effect of MMP2 in hearts during global ischaemia-reperfusion 
and its impact on the recovery of the mechanical function of the LV. In human studies 
carried out by Spinale and co-workers 140, MMP activity was found to return to baseline 
levels with diastolic arrest of the heart with cardioplegia. However, it was difficult to 
ascertain whether this was due to a direct effect of the cardioplegic solution or to the 
fact that hypothermia was also used as a cardioprotective strategy. The low temperature 
will undoubtedly affect the activity of biological enzymes. In our studies, hypothermia 
was not used.  
It was difficult to draw any substantial conclusion in our study regarding the effects of 
MMP inhibition and the timing of inhibition on metabolic activity in the hearts during 
ischaemia. During ischaemia, the time taken to develop contracture and to reach peak 
contracture were both delayed in Group (iii), although the delay to reach peak 
contractures was not significantly different in Group (iii) compared to the other groups. 
The data suggested that MMP inhibition should be present before, during and after 
ischaemia to affect the metabolic activity in the infarcted myocytes during the 
subsequent global ischaemia.   
In an experimental study, Yeh and co-workers 144 postulated that upregulation of pro-
inflammatory genes via the nuclear factor (NF)-κB also activates MMPs, causing 
myocardial dysfunction associated with cardiopulmonary bypass and global ischaemia 
induced during surgery. They pretreated rabbits with curcumin, a food derivative known 
to inhibit the activation of NF-κB pathway, 2 hours prior to institution of 
cardiopulmonary bypass with cold cardioplegia protection and global ischaemia of 60 
min. At 4 hours of reperfusion, they found that inflammatory markers in the plasma 
were reduced, together with reduced troponin I and attenuation of myocardial MMP2 
and MMP9 at the end of reperfusion. This correlated with improved recovery of 
myocardial contractility in the curcumin-treated groups.   
In our model, we examined the early phase of reperfusion i.e the initial hour of 
reperfusion following 60 min of global normothermic ischaemia, with normothermic 
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infusion of cardioplegia solution. The MMP inhibitor was delivered directly to the 
myocardium with cardioplegia, hence eliminating the issue of bioavailability, as might 
occur in subcutaneous injections of drugs.  
The above results showed that, in terms of the trend of recovery, there was a significant 
difference between the groups. The difference is especially marked during the early 
reperfusion period (within 30 min of reperfusion); with significantly better recovery of 
LVDP in the group where MMP inhibition was present before, during and after 
ischaemia (Group iii) compared to the group when MMP inhibition was only present 
during and after ischaemia (Group v). This implied that MMP2 has a contributory role 
during both ischaemia and reperfusion in causing mechanical dysfunction in the 
infarcted hearts. This could have an impact clinically if these observations are also seen 
in patients. A faster and better recovery during the early post-operative period could 
imply less inotropic support and intensive care management. Nonetheless, with further 
reperfusion period, the recovery of the hearts seemed to converge somewhat and the 
final LVDP recovery achieved in each group was not statistically significant. Due to the 
different protocol of MMP inhibitor tested, there were too many groups generated. 
Hence, this makes the statistical analysis less powerful and robust. It would have been 
ideal to only compare a few groups at a time. But, different timing of MMP inhibitor 
added may have implications in the recovery of the heart, so it was essential that these 
different protocols were tested. 
It may also be that St Thomas’ cardioplegia protects the heart, even the infarcted hearts, 
adequately that 60 min of global normothermic ischaemia was not sufficient to induce 
considerable injury to the hearts. Perhaps, a longer ischaemic time, such as 90 min, that 
would have induced more ischaemic injury and thus lower recovery of function may 
have generated conditions where any additional protective effects of MMP inhibition 
could have been disclosed. Alternatively, St Thomas’ cardioplegia may actually have an 
effect on MMP2 activity. It may have been useful to sample the myocardium at mid-
ischaemia and reperfusion to study the activity of MMP2 and metabolic state of the 
infarcted hearts. The other disadvantage of the model is due to a more general nature of 
MMP inhibition by 1,10-phenanthroline. Perhaps, a MMP2-selective inhibitor such as 
444285, may result in better cardioprotection with selective MMP2 inhibition.   
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It was interesting to note that the volume of second infusion of cardioplegia was 
significantly better in Group (iii), which incidentally had the best recovery profile. 
MMP2 inhibition may better protect the endothelium of the coronary arteries, hence 
resulting in better overall recovery of mechanical function.  
In conclusion, St Thomas’ cardioplegia solution protected the infarcted hearts 
sufficiently well, even with 60 min of global normothermic ischaemia, such that there 
was reasonable recovery of mechanical function with reperfusion. Addition of a MMP 
inhibitor, 1,10-phenanthroline, before, during and after ischaemia, resulted in a trend 
towards an improved recovery profile, although the final recovery did not achieve 
statistical significance. On the other hand, if MMP inhibition was only introduced 
during and after ischaemia, it seemed to have a detrimental effect on myocardial 
function. This suggests that MMP2 may be an active player in the myocardium during 
ischaemia as its inhibition prior to ischaemia seems essential to offer some degree of 
cardioprotection. More work in the future, involving longer ischaemic time such as 90 
or 120 min of global ischaemia and by using irreversible and specific MMP2 inhibitor 
will need to be carried out to further define the effect of cardioprotection of hearts using 
St Thomas’ cardioplegia with MMP2 inhibition. 
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8 DISCUSSION AND CONCLUSION 
8.1 Thesis aims and objectives 
Since the seminal discovery of MMPs by Gross and Lapiere 9, there has been rapid 
progress in MMP research. The role of MMPs, which were originally seen as 
destructive enzymes involved in the regulation of the ECM, has now evolved into 
essential cell-signalling regulators in acute pathophysiology, such as acute ischaemia-
reperfusion injury in the heart. The effects of MMPs have been investigated in various 
settings of acute ischaemia-reperfusion as described in Chapter 1 35, 42, 140, 142. The 
present study was undertaken to investigate the influence of MMP2 in regional 
infarction followed by global ischaemia-reperfusion as would occur in patients with 
ACS undergoing urgent cardiac surgery. This group of patients is becoming 
increasingly more common in clinical practice as diagnostic tests become more 
sensitive and specific as well as better understanding of the pathophysiology leading to 
expeditious treatment. In the UK, patients who underwent CABG within a month of 
their MI had almost doubled over a 4-year period (between 2004 to 2008) 70. Current 
ESC/EACTS guidelines encourage aggressive management of revascularisation, 
including surgical revascularisation in high-risk patients 67. Yet, subjecting infarcted 
hearts to further global ischaemia during surgery may have its detrimental effects. This, 
in some ways, is manifested in the higher mortality seen in this group of patients. 
Molecular pathways such as MMPs, activated by the initial infarction, may render the 
myocardium more vulnerable to further ischaemic insult, especially if the insult is 
imposed shortly after the initial injury 42. The duration of MI and cardiac surgery is 
suggested to influence surgical outcome as discussed in Chapters 1 and 5, but the 
threshold is contentious. Hence, as well as investigating the role of MMP2 in this 
setting, the influence of interval between an initial MI and global ischaemia was also 
explored. 
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8.2 The rat in vivo LAD ligation model and isolated Langendorff 
(heart) perfusion 
Rodents were used in these studies for several reasons. It is cheaper and logistically 
feasible to carry out larger number of experiments. In vivo myocardial infarction model 
in rats by surgical LAD ligation is an established and reliable method to create 
consistent MI as mentioned in Chapter 3. The results presented in Chapter 3 confirmed 
that the final infarct size obtained in the hearts after LAD ligation was consistent.  
Although it is common to occlude various coronary arteries during isolated Langendorff 
heart perfusion, as far as we are aware, there was no previous study with established 
infarcted hearts (>24 hours) perfused in the isolated Langendorff perfusion model. The 
stability studies carried out in Chapter 3 showed that infarcted hearts (7 days post LAD 
ligation) were stable over a 120 min aerobic perfusion period; comparable to perfusion 
of normal hearts. A slightly higher LVEDP was noted in infarcted hearts compared to 
normal hearts, but neither the LVEDP after 20 min of equilibration with aerobic 
perfusion nor the change in LVEDP at the end of the perfusion period was significantly 
different. Pressure-volume relationship in the hearts may be an over-simplified way of 
assessing the mechanical function and contractility of the myocardium, especially in 
infarcted hearts. There may have been asymmetrical changes in the LV geometry and 
stiffness 100; in addition, presence of an inflated balloon may also alter the intrinsic 
contractility of the heart. Other more sophisticated way of assessing functional recovery 
such as length-tension relationship could be used, but previous work undertaken in the 
laboratory showed that it did not add much more information to the study 145. Hence, we 
choose to accept and acknowledge the limitations of the technique. As all groups were 
subjected to the same treatment, it is still a valid way of comparison.  
Although rodents may be suitable to establish a proof-of-principle, the results obtained 
here may not be directly extrapolated to human. The remodelling process following MI 
in rat hearts may be different to human; it may be shorter and hence in 7 days, there 
may be some degree of adverse remodelling in the LV, which could explain the results 
seen in Chapter 4, Section 4.3.2. Hence, the infarcted rat hearts used in this study may 
not accurately represent adult human infarcted hearts 7 days after MI.  
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8.3 MMP2 and acute mechanical dysfunction in infarcted hearts 
subjected to another global ischaemic burden 
With the present study, we found that when systemic factors were removed from the 
study design, infarcted hearts, when subjected to global ischaemia-reperfusion 7 days 
after the initial MI, had less capacity to recover its contractile function in an isolated 
heart model, compared to infarcted hearts subjected to the same ischaemic insult 3 days 
after the initial MI. As highlighted in the discussions in Chapter 4, Sections 4.1 and 4.4, 
different clinical series reported different outcomes regarding the mortality of CABG 
and the interval between MI and surgery 66, 71, 101, 103-106. It is very difficult to accurately 
dissect out the important factors causing the increased mortality. Patient groups were 
very heterogenous and the clinical presentation and haemodynamic status at 
presentation and prior to surgery were also very diverse. Hence, our model offers the 
advantage of removing all these confounding factors, with focus solely on the biology 
of the infarcted myocardium as a variable. The findings were unexpected. One would 
have thought that with longer interval between MI and global ischaemia, the infarcted 
hearts would have had more time to recover and will be able to withstand the 
subsequent insult better. The second window of protection may explain the result we 
see in better recovery of function in infarcted hearts, when subjected to global ischaemia 
3 days after MI 146. The ischaemic triggers initiate a cascade of signalling of events 
resulting in protein synthesis, post-translational protein modification and a change in 
compartmentalisation of existing proteins, which in the second window of protection 
lasts for up to 72 hours following the ischaemic insult.  
When we correlated the physiological effects with molecular events, specifically with 
myocardial MMP2 activity, we did find that MMP2 activity was significantly elevated 
in the infarcted hearts (Chapter 5). Petersen and co-worker showed that MMP2 protein 
level was elevated at day 1 post MI and remained elevated for a few weeks 33, but it is 
not known what happens to the protein level or the activity of MMP2 in the first week 
following MI. Unfortunately, due to the constraint of time, MMP2 activity was only 
interrogated in infarcted hearts 7 days after the initial MI. It would have been very 
informative to investigate MMP2 activity in infarcted hearts 3 days after MI to see how 
it correlates with the physiological phenomenon.  
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8.4 Assay of MMP2 activity 
There are numerous ways to assay MMP2 and its activity 86, 120; the most appropriate 
assay chosen depending on the objectives of the study. As this study primarily explores 
the role of MMP2 in mechanical dysfunction in infarcted hearts subjected to further 
global ischaemia-reperfusion, assays using native proteins, such as substrate 
zymography or immunocapture assays, are most suitable. Zymography was not used as 
the principal assay as the detection of gelatinolytic activity was based solely on 
molecular weight. Hence, an immunocapture assay was used in the study as it captured 
active MMP2, regardless of the molecular weights.  
The other significant problem with either assay was that both are in-vitro assays. 
Therefore, it does not reflect the true activity of MMP2 in the tissues as MMP2 
complexed to its endogenous inhibitors such as TIMPs, may be dissociated during tissue 
processing and during the assay itself. The assays carried out this way with whole heart 
tissue homogenisation does not give us any information about the location of active 
MMP2 within the myocardium. MMP2 may be activated at different cellular location 
such as the mitochondria or in the nucleus, and at different times during ischaemia and 
reperfusion. It may be better to use in-situ assay such as microdialysis method using 
fluorogenic substrates. It may provide more information about the overall MMP2 
activity level in the tissues and the localisation of MMP2 activity. Unfortunately, these 
techniques are more complicated and costly in terms of equipment, and it was not 
readily available in the laboratory currently. Nevertheless, the in-vitro assays used were 
adequate to achieve the aims set out in this study.  
8.5 Cardioplegia studies in infarcted hearts with and without 
MMP inhibitor 
There were not many studies investigating the effects of cardioplegia on MMP activity 
139, 140, 142. Our data suggested that MMP2 has a role to play in causing mechanical 
dysfunction in infarcted hearts when subjected to further global ischaemia-reperfusion. 
Hence, the possibility that MMP inhibition could be used in conjunction with 
cardioplegia solution to protect the ischaemic heart better to withstand further ischaemic 
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insult was an exciting prospect. Different protocols of MMP inhibition were designed as 
the timing of MMP inhibition may impact the functional recovery of the infarcted heart 
123. We found that MMP2 inhibition must be present before, during and after ischaemia 
to confer better cardioprotection of the heart, especially during the early phase of 
reperfusion; allowing a more rapid recovery rate of the mechanical function of the heart 
compared to hearts where MMP2 inhibition was only present during and after 
ischaemia. 
Given these results, it may have been prudent to further investigate the effect of 
cardioplegia on MMP2 activity. It would have been useful to assess myocardial MMP2 
activity at various times of the perfusion protocol with and without cardioplegia 
protection; such as after aerobic equilibration, at mid-ischaemia and at early 
reperfusion.  
8.6 Limitations 
We acknowledge that there are inherent limitations with the experimental set-up and 
protocols and most of these were discussed in the relevant chapters. We have tried to 
design a suitable animal model, using the most suitable resources available to us, to 
study a clinically relevant issue. This, we hope will allow better integration of pre-
clinical and clinical research so that we can maximise the output of research, as 
advocated recently by various researchers 59, 89, 147.  
One essential disadvantage of the study is the use of small animal, rodents, in this case. 
There are bound to be subtle differences in certain molecular pathways and metabolic 
activities compared to the physiology and the responses to pathological processes in the 
human. The rats we used were young adult, male rats. These rats were not equivalent to 
a typical 65 year-old man who presents with ACS, requiring surgery within 7 days of 
their ACS. The fundamental pathological changes and processes within the myocardium 
and endothelium will be absent in the rodent species, with the absence of co-morbidity 
such as hyperlipidaemia, diabetes and hypertension. We will also not know the 
influence and interaction of various cardiovascular medications such as statins and anti-
hypertensive drugs on the MMP2 activity in this context.   
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Besides, although isolated Langendorff heart perfusion confers the benefits of removing 
the confounding effect of systemic interaction, it is also a distinct disadvantage as these 
interactions may be important and may have significant impact on the recovery of the 
heart following acute ischaemia-reperfusion.  
8.7 Future work 
There are a lot more questions that need to be answered. A more thorough investigation 
of the haemodynamic status of the infarcted hearts could be carried out using 
transthoracic echocardiography and invasive pressure-volume catheterisation. This 
would allow us to document the serial haemodynamic and regional work changes in the 
LV from MI to just prior to excision for ex-vivo heart perfusion. Further 
characterisation of MMP2 activity in early infarct (i.e 3 days post LAD ligation) hearts 
during subsequent global ischaemia-reperfusion needs to be carried out. This way, we 
will be able to see how MMP2 activity in infarcted heart changes within the first 7 days 
of LAD ligation and whether, the changes in the activity at day 3 and day 7 post ligation 
may explain the mechanical dysfunction seen in Chapter 4, Section 4.3.2. It may also be 
more informative to have a way of assessing the in-situ MMP2 activity within the 
myocytes. Additionally, the activity during ischaemia itself may clarify further the role 
of MMP2 during the ischaemic period.  
The effect of irreversible and specific MMP2 inhibition should also be explored as an 
adjunct to St Thomas’ cardioplegia in cardioprotection of infarcted hearts. The 
ischaemic time should be extended to either 90 or 120 min and the infarcted hearts 
should also be sampled at baseline aerobic perfusion, during mid-ischaemia, 
immediately after ischaemia and at 10 min of reperfusion to assess MMP2 activity in 
the heart with St Thomas’ cardioplegia with and without MMP2 inhibition. This may 
show us the effect of St Thomas cardioplegia on MMP2 activity in the infarcted hearts 
and whether MMP2 inhibition will make any significant impact.  
8.8 Conclusion 
In conclusion, in these studies, we attempted to examine a relevant and significant 
clinical problem using a simple experimental technique based entirely in the laboratory. 
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We have established that it is feasible to use acute in-vivo surgical LAD ligation model 
to induce MI in rat hearts and subsequently harvest the hearts within 7 days of MI for 
use in ex-vivo heart perfusion. The preparation is stable over at least a 120-min 
perfusion period, without significant deterioration in function. This is an invaluable 
model that allows us to study in detail biological and molecular events within the hearts, 
and relating these events to physiological function, when subjected to 2 separate but 
subsequent ischaemic stress. We conclude that infarcted hearts, when subjected to 
further global ischaemia-reperfusion injury, had less capacity to recover its contractile 
function, and that the impact was more significant in infarcted hearts 7 days after LAD 
ligation compared to 3-days post ligation. The functional impairment was associated 
with higher myocardial MMP2 activity. Inhibition of MMP2 ameliorated the 
dysfunction leading to improved recovery of mechanical function. Within the 
limitations of the experimental design, we see an inference in the link between the 
physiological effects and molecular events, further strengthened by functional 
improvement with molecular evidence of MMP2 inhibition.  
MMP inhibition, when present before, during and after ischaemia, in hearts protected by 
St Thomas’ cardioplegia, also resulted in significantly faster and better recovery during 
the early reperfusion period compared to hearts when MMP inhibition was only present 
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